

Novel aspects of the apolipoprotein-E receptor family: regulation and functional role of their proteolytic processing

Jorge A. LARIOS^{1,2}, Maria-Paz MARZOLO (✉)^{1,2}

¹ *Laboratorio de Tráfico Intracelular y Señalización, Departamento de Biología Celular y Molecular, Pontificia Universidad Católica de Chile, Alameda # 340, Santiago, Chile*

² *Millennium Nucleus in Regenerative Biology (MINREB), Facultad de Ciencias Biológicas, Pontificia Universidad Católica de Chile, Alameda # 340, Santiago, Chile*

© Higher Education Press and Springer-Verlag Berlin Heidelberg 2012

Abstract Studies related to the functional and regulatory aspects of proteolytic processing are of interest to cell biologists, developmental biologists and investigators who work on human diseases. Much of what is known about this topic derives from the study of the proteolytic processing of the amyloid precursor protein (APP), which is involved in the pathology of Alzheimer's disease, and of the Notch protein and its Delta ligand, which play roles during embryonic development and in biologic processes in the adult. The proteolytic processing of plasma membrane receptor proteins is under the control of different enzymes that are responsible for releasing the ectodomain into the extracellular environment, where it has the potential to function as a signaling molecule and/or regulate the availability of the receptor's ligand. Following shedding of the ectodomain, the γ -secretase enzymatic complex cleaves the transmembrane domain and releases the cytoplasmic domain (ICD) of the receptor. The ICD can function in the cytoplasm and/or at the nucleus.

Members of the low-density lipoprotein receptor (LDLR) family are endocytic-signaling proteins that perform a wide variety of physiologic functions during development and in the adult life. In addition these receptors have been implicated in a variety of diseases in adults. The prototypic receptor for this family of proteins is the LDLR itself. Besides their binding to apolipoproteins, these receptors bind many ligands that are destined for internalization and degradation. Some ligands have signaling properties. The proteolytic processing of certain members of the LDLR family not only controls receptor availability at the cell surface but also has functional consequences that amplify the spectrum of roles that these receptors perform. In addition, many complex regulatory mechanisms control the proteolytic processing of these receptors.

Keywords ADAM, APP, LDLR, LRP, metalloproteinase, secretase

Introduction

Proteolytic processing of membrane proteins, including several types of receptors, is a central and relevant mechanism that operates in many biologic processes, including development, cell migration, cell signaling, neurodegenerative diseases and cancer. This processing is a general mechanism that involves several enzymes that include secretases of the ADAM-metalloproteinase family, the aspartyl-protease

BACE1, the γ -secretase complex and diverse membrane proteins that are recognized as substrates (Vassar et al., 1999; Vassar, 2001; Huovila et al., 2005; Edwards et al., 2008; Wakabayashi and De Strooper, 2008). Proteolytic processing results in the production of receptor extracellular domains that are mainly produced by shedding, membrane fragments that include the transmembrane and cytoplasmic domains of the proteins and the intracellular domain (ICD), which is produced by intramembrane proteolysis (RIP) (Wakabayashi and De Strooper, 2008). The products of proteolysis can possess activities of their own, for example, the ectodomains of the epidermal growth factor receptor family act as ligands for signaling receptors (Higashiyama and Namba, 2005) and in the Notch/delta system, ICDs regulate gene expression

Received September 15, 2011; accepted October 26, 2011

Correspondence: Maria-Paz MARZOLO

E-mail: mmarzolo@bio.puc.cl

(Fortini, 2009).

The ectodomain proteolytic processing of many receptors is produced by the action of zinc-dependent metalloproteinase family. A subgroup within this family is constituted by the endopeptidases, among which are the ADAMs (a disintegrin and metalloproteinase) and MMPs (matrix metalloproteinases). ADAMs are integral membrane proteins that possess disintegrin and metalloproteinase activities (Huovila et al., 2005). This family of proteins has more than 40 members, 13 of which have enzymatic activity and are involved in embryonic development and in several biologic processes in the adult (Edwards et al., 2008). ADAM knockout mice (ADAM 10, 17 or 19) exhibit embryonic or early postnatal lethality, therefore the study of these metalloproteinases is important (Huovila et al., 2005; Edwards et al., 2008). These enzymes participate in signaling processes, and they are regulated by genetic and post-translational mechanisms (Box1). On the other hand, MMPs are also related to the shedding of various proteins. Many of them are secreted into the extracellular medium, resulting in the proteolytic processing of cell adhesion proteins, growth factor precursors proteins, immunomodulators and receptors (Hayashida et al., 2010). For example MMP-2 sheds syndecan-2 (Fears et al., 2006), a cell adhesion molecule, and MMP-3 can shed Fas ligand (Matsuno et al., 2001) and also the Heparin-binding EGF-like growth factor (HB-EGF) (Suzuki et al., 1997). There are integral and associated membranes MMPs (Massova et al., 1998). The membrane Type 1-Matrix Metalloproteinase MT1-MMP is crucial during development, since mice deficient in this protease have problems in the

remodeling of skeletal and extracellular connective tissues triggering early death (Holmbeck et al., 1999). MT1-MMP degrades various components of the extracellular matrix, including collagen I, II and III (Ohuchi et al., 1997), and also acts as a sheddase, processing the ectodomain of hyaluronan receptor CD44 (Kajita et al., 2001), syndecan-1 (Endo et al., 2003) and tumor necrosis factor-related activation-induced cytokine (Schlöndorff et al., 2001), among others (Karsdal et al., 2002; Mu et al., 2002).

Many studies of the molecular and cellular determinants of proteolytic processing have used the amyloid precursor protein (APP) because of its relevance in Alzheimer's disease (AD) and the Notch/Delta system because of the central role it plays in human disease and in determining cell fate and pattern formation during development. APP can be processed by two pathways. In the amyloidogenic pathway, BACE1 cleaves APP, which releases β APP and produces the membrane-bound fragment β CTF (Vassar et al., 1999; Wakabayashi and De Strooper, 2008; Lichtenthaler et al., 2011). β CTF is further processed by the γ -secretase complex (Wakabayashi and De Strooper, 2008), producing A β peptides and the intracellular cytoplasmic domain of APP (AICD). In the second pathway (non-amyloidogenic), the first cut is catalyzed by an α -secretase (possibly ADAM 10 or 17) (Buxbaum et al., 1998; Kuhn et al., 2010; Jorissen et al., 2010), producing an sAPP α and the corresponding CTF α . Depending on the activation system, other proteases may be involved (Delarasse et al., 2011). The γ -secretase complex processes CTF α , generating the non-amyloidogenic peptide p3 and the AICD. The comprehensive study of the

Box 1

Many proteases belong to the ADAMs family, and 13 of them are proteolytically active and are expressed in human tissues (Edwards et al., 2008). ADAMs have many substrates (Edwards et al., 2008) and several mechanisms regulate their activity:

1) **Genetic regulation** This mechanism includes the increase in ADAMs *gene expression* induced by cytokines or in cancer, and the existence of *alternative splicing* and *inducible promoters* that are present in several of the genes encoding these proteinases (Murphy, 2009).

2) **Post-translational regulation and trafficking** The mature forms of ADAMs that have proteolytic activity require the proteolytic *processing of their pro-domain to function* properly. For example, ADAM 12, 17 and 33 undergo pro-domain maturation, but the peptide still interacts with the mature ADAM and, consequently, regulates protease activity. *Location*. ADAMs are located in perinuclear regions, but they are also found in lesser amounts at the cell surface, it being the location of choice for processing many of their substrates, such as adhesion proteins and surface receptors (Reiss et al., 2006; Murphy, 2009). However, active forms of ADAMs are also found in intracellular compartments (Shirakabe et al., 2001; Yokozeki et al., 2007); for example, ADAMs 10/17 induces shedding of APP in the trans-Golgi network (TGN) (Skovronsky et al., 2000). *ADAMs and lipid rafts*. The active forms of ADAM17 and ADAM19 are associated with lipid rafts (Wakatsuki et al., 2004; Tellier et al., 2006; Thiel and Carpenter, 2006; Takaguri et al., 2011), and it is in this microdomain where ADAM17 exerts its proteolytic activity on TNF α , TNFR I and II (Tellier et al., 2006) and the ligand-induced shedding of ErbB4 (Thiel and Carpenter, 2006). In contrast, other studies postulate that ADAM 10 and ADAM 17 are not associated with lipid rafts (Kojro et al., 2001; von Tresckow et al., 2004; Zimina et al., 2005; Gil et al., 2007; Harris et al., 2009), but many of their substrates are partitioned in these membrane domains (Tellier et al., 2006). Consequently, the shedding of these proteins is spatially regulated. Therefore, cholesterol depletion that disrupts lipid rafts increases the processing of some ADAMs substrates, such as TNF α , TNFR I and II (Tellier et al., 2006), IL-6R (Matthews et al., 2003), CD3 (von Tresckow et al., 2004), collagen XVII (Zimina et al., 2005) and APP (Kojro et al., 2001).

3) **Intracellular signaling regulation** The cytoplasmic region of ADAMs have motifs that interact with *cytosolic protein* domains, including SH3, SH2, PDZ, WW, EVH1 and 14-3-3 (Huovila et al., 2005). The cytoplasmic domains are phosphorylated at Tyr, Ser and Thr residues. *Phorbol esters* have been widely used to activate ADAMs and induce the shedding of their substrates (Huovila et al., 2005). *Oxidative stress, UV and intracellular calcium concentrations* are also involved in ADAMs regulation (Huovila et al., 2005; Murphy, 2009). Among the *cellular mediators* involved in these processes are the following: protein kinase C (PKC), the mitogen-activated protein (MAP) kinases p38 and ERK, which also modulate constitutive shedding, and the activation of *G protein-coupled receptors* (GPCR) (Murphy, 2009). Intracellular signaling affects the cellular localization of ADAM 12, ADAM 10 and ADAM 17 (Peiretti et al., 2003; Sundberg et al., 2004; Soond et al., 2005; Marcello et al., 2007), and the *phosphorylation* of ADAMs (Izumi et al., 1998; Diaz-Rodríguez et al., 2002; Zheng et al., 2002; Fan et al., 2003; Soond et al., 2005; Zhang et al., 2006; Lemjabbar-Alaoui et al., 2011), which are processes that in some cases, might be involved in regulating their own proteolytic activity (Diaz-Rodríguez et al., 2002).

mechanisms involved in APP processing and trafficking has allowed the discovery of many relevant aspects of the cell biology of these processes that can be applied to the proteolytic processing of other substrates.

In the Notch/Delta system, signaling depends on the proteolytic processing of the Notch receptor in three sequential steps (Fortini, 2009). The first cut is mediated by furin and it occurs during biosynthesis of the protein, probably in the Golgi apparatus (Blaumueller et al., 1997; Logeat et al., 1998). Once the receptor reaches the plasma membrane and is in contact with a ligand presented by a neighboring cell, the receptor is processed by metalloproteinases of the ADAM family, resulting in a membrane Notch-associated C-terminal fragment (NCTF) that is a substrate of the γ -secretase complex. The NICD that is produced by the action of γ -secretase translocates to the nucleus to regulate gene transcription (Fortini, 2009). The participation of the γ -secretase complex in various physiologic processes, such as the Notch signaling pathway, is the rationale for avoiding the use of inhibitors that selectively block the activity of this

complex to treat AD. The γ -secretase complex that performs RIP consists of four essential transmembrane proteins, specifically, presenilin (has aspartyl protease activity), nicastrin, Aph-1 and Pen-2, which form a complex with a 1:1:1:1 stoichiometry. There is preferential processing of substrates that have an N terminus that faces the extracellular environment and are no more than 50 aminoacids from the transmembrane domain. The protease responsible for proteolytic processing of the intramembrane region of the substrate has less specificity because there is no clear-cut consensus cleavage site, and multiple cleavage sites can be found on the same substrate (Wakabayashi and De Strooper, 2008).

Among the recently recognized substrates of the γ -secretase complex are members of LDLR or the apolipoprotein-E receptor family. Members of this receptor family include LDLR, LRP1, LRP1b, megalin/LRP2, ApoER2, VLDLR and LRP5/6 (Fig. 1). These proteins and their ligands play important roles in development, in biologic processes in adults and are associated with diverse pathologies (Herz and




Figure 1 Schematic representation of members of the LDLR family. Members of the LDLR family share common structural motifs, including ligand binding repeats, epidermal growth factor repeats, YWTD spacer domains, a single transmembrane domain, and a short cytoplasmic domain containing at least one conserved NPXY endocytic motif that binds to adaptor proteins to regulate internalization and recycling. The same motif may play a role in the recruitment of signaling adaptor proteins. The LRP5/6 receptors are a subclass of this family that lacks some structural features, such as the ligand binding repeats and the NPXY cytosolic motifs.

Willnow, 1994; Willnow, 1999; Willnow et al., 1999; Marzolo and Farfán, 2011). These receptors are type I membrane glycoproteins and have structural similarities, including a large extracellular domain, a transmembrane domain and a relatively short cytoplasmic tail. They share common features that include the following: 1) ligand-binding complement-type repeats, 2) epidermal growth factor (EGF) receptor-like repeats, 3) YWTD β -propeller domains, 4) a cytoplasmic tail that contains at least one Asn-Pro-X-Tyr (NPXY) motif, which is normally responsible for receptor interactions with intracellular adaptor proteins (Table 1) regulating their coupling to specific trafficking and/or signal transduction pathways. In addition, almost all of the receptors require the assistance of endoplasmic reticulum chaperones, such as receptor-associated protein (RAP) (Willnow et al., 1996c; Czekay et al., 1997; Bu and Schwartz, 1998; Bu and Marzolo, 2000) and mesoderm development (MESD) (Culi and Mann, 2003; Hsieh et al., 2003; Culi et al., 2004; Lighthouse et al., 2010) for the correct folding of the extracellular domains.

Members of the apolipoprotein E family are classically recognized as endocytic receptors that mediate the internalization and degradation of a variety of ligands, and LDLR is the first described and prototypic member responsible for the catabolism of low-density lipoproteins (Goldstein et al., 1985; Brown and Goldstein, 1986). In addition to the role of these receptors in endocytosis, especially in the case of LRP5/6 and ApoER2, ligand binding triggers signaling pathways that have relevant physiologic functions in development and also in the adult life (Stockinger et al., 2000; Beffert et al., 2002; Assadi et al., 2003; Bock and Herz, 2003; Beffert et al., 2005; Li and Bu, 2005; Simó et al., 2006; Sentürk et al., 2011).

In this review, we discuss the evidence that supports the proteolytic processing of these receptors, how the processing

is regulated and potential functional roles for the proteolytic fragments that are produced in the different cell systems in which these membrane proteins are found.

LRP1: an endocytic and signaling receptor

Structure and function of LRP1

LDL receptor-related protein 1 (LRP1) is a large endocytic receptor (Fig. 1) that is widely expressed in several tissues and systems, such as the liver (hepatocytes and macrophages), vascular tissue, adipose tissue, the central nervous system (blood-brain barrier (BBB), neurons and glial cells) and the immune system (Lillis et al., 2008). This glycoprotein, which is synthesized as a polypeptide chain of more than 600 kDa, was initially discovered as the receptor that endocytoses the plasma protease inhibitor α 2-macroglobulin (α 2M) (Moestrup and Gliemann, 1989; Kristensen et al., 1990; Strickland et al., 1990), tissue type plasminogen (tPA) (Bu et al., 1992b; Bu et al., 1993; Bu et al., 1994) and apolipoprotein E, being responsible for chylomicron remnant clearance (Beisiegel et al., 1989). Currently, LRP1 is known to interact with at least 30 different ligands, including apolipoproteins, proteases, protease inhibitors, extracellular matrix proteins, and membrane proteins such as APP (Kounnas et al., 1995; Knauer et al., 1996; Pietrzik et al., 2004) and the urokinase-type plasminogen receptor (uPAR) (Nykjaer et al., 1992; Lillis et al., 2008) indicating LRP1 participation in many biologic processes. Because genetically modified mice that do not express LRP1 die during gestation, this receptor is critical for development (Herz et al., 1992a). The extracellular region of LRP1 (N-terminal) contains four ligand-binding repeats, the second and fourth of which exhibit stronger interactions with ligands (Neels et al., 1999).

Table 1 LDLRs intracellular adaptors

Receptor	Intercellular interacting proteins	Reference
APOER2	*JIP1	Stockinger et al., 2000
	*JIP2	Stockinger et al., 2000
	*PSD95	Gotthardt et al., 2000
	*Talin homolog	Gotthardt et al., 2000
	*APC subunit 10	Gotthardt et al., 2000
	*ICAP-1	Gotthardt et al., 2000
	*X11/	He et al., 2007
	Dab1	Trommsdorff et al., 1999
	Fe65	Hoe et al., 2006
	SNX17	Stockinger et al., 2002
	Dab2	Cuitino et al., 2005
	ARH	Jones et al., 2003
VLDLR	SNX17	Stockinger et al., 2002
	Dab1	Trommsdorff et al., 1999
	ARH	Jones et al., 2003
LRP1	JIP1	Stockinger et al., 2000
	JIP2	Stockinger et al., 2000

(Continued)

Receptor	Intercellular interacting proteins	Reference
	Dab1	Trommsdorff et al., 1998
	PSD95	May et al., 2004, Gotthardt et al., 2000 Martin et al., 2008
	Mint2 (X11-like)	Gotthardt et al., 2000
	Fe65	Trommsdorff et al., 1998
	ARH	Jones et al., 2003
	SNX17	Stockinger et al., 2002 van Kerkhof et al. 2005, Betts et al., 2008
	Homolog of PIP 4, 5 kinase	Gotthardt et al., 2000
	CED-6/GULP	Su et al., 2002
	ShcA	Barnes et al., 2001
	Na channel 3	Gotthardt et al., 2000
	APC subunit 10	Gotthardt et al., 2000
	Cbl	Takayama et al., 2004
	Shp2	Betts et al., 2008
	PICK1	Shiroshima et al., 2009
	RanBPM	Shiroshima et al., 2009
	PKB	An et al., 2008
	CSK	Guttman et al., 2009
	PI3K p85	Guttman et al., 2009
	CamKII	Guttman et al., 2009
	PLC	Guttman et al., 2009
LRP1b	JIP1b	Shiroshima et al., 2009
	JIP2	Shiroshima et al., 2009
	PICK1	Shiroshima et al., 2009
	RanBPM	Shiroshima et al., 2009
	SNTG2	Shiroshima et al., 2009
	Grb7	Shiroshima et al., 2009
	PSD95	Marschang et al., 2004
	AIP	Marschang et al., 2004
Megalin	JIP1	Gotthardt et al., 2000
	JIP2	Gotthardt et al., 2000
	PSD95	Gotthardt et al., 2000
	PIP4,5 kinase homolog	Gotthardt et al., 2000
	Mint2 (X11-like)	Gotthardt et al., 2000
	Dab1	Gotthardt et al., 2000
	ICAP-1	Gotthardt et al., 2000
	ARH	Jones et al., 2003; Nagai et al., 2003
	MegBP	Petersen et al., 2003
	Dab2	Oleinikov et al., 2000
	Fe65	Alvira-Botero et al., 2010
	PKB	Caruso-Neves et al., 2006
	ANKRA	Rader et al., 2000
	MAGI-1	Patrie et al., 2001
	GIPC	Lou et al., 2002
LRP5/6	Axin	Mao et al., 2001; MacDonald et al., 2011
	Frat1	Hay et al., 2005
	GSK3	Mi et al., 2005

The cytoplasmic regions of the members of the LDLR protein family that undergo proteolytic processing interact with various intracellular adaptors. These interactions allow the performance or regulation of multiple cellular and physiologic functions, including receptor trafficking, processing, signaling and scaffolding.

Receptor	Transmembrane and cytosolic sequence	Number of amino acids
ApoER2	<i>VIGIIVPIVVIALLCMSGYLMWRNWKRNKTKSMNFDNPVYRKTTEEEDEDELHIGRTA</i> <i>QIGHVYPAAISSFDRPLWAEPCLGETREPDPAPALKEFLVLPGEPRSQLHQLPKN</i> <i>PLSELPVVKSKRVALSLEDDGLP</i>	137
ApoER2 Δpro	<i>VIGIIVPIVVIALLCMSGYLMWRNWKRNKTKSMNFDNPVYRKTTEEEDEDELHIGRTA</i> <i>QIGHVYPA-----</i> <i>-----RVALSLEDDGLP</i>	78
LDLR	<i>AAWAILPLLLLVMMAVGGYLMWRNWXHKNMKS MNFDNPVYLKTTTEEDLSIDIGRHS</i> <i>ASVGHTYPAISVVSTDDDLA</i>	76
LRP1	<i>HIASILIPLLLLLLVLAGVVFYKRRVQGAQGFQHRMTNGAMNVEIGNPTYKMYE</i> <i>DGGLLDPGFMIDPTKARYIGGGPSAFKLPHTAPPYLNLSDLKGLTAGPTNYSNPVY</i> <i>GFPEIDGDLA</i>	125
LRP1b	<i>AIIVPLVLLVTLITLVLIGLVLCRKRRTKTIRRQPIINGGINVEIGNPSYNMYEVDHHDN</i> <i>DGGLLDPGFMIDPTKARYIGGGPSAFKLPHTAPPYLNLSDLKGLTAGPTNYSNPVY</i> <i>AKLYMDGQNCRNLSGVSVERKELLPKKIEIGIREVA</i>	155
Megalin	<i>AVAVLLTILLIVVIGALAIAGFFHYRRTGSLPALPKLPSLSSLVKPSSENGVTFRSGA</i> <i>DLNMDIGVSGFGPETADRSMAMSEDFVMEGKQPIIFENPMYSARDSAVKVVQPIQ</i> <i>VTVSENVDNKNYGSPIINSEVPETNPTSPAADGTQVTKWNLFKRKSQTTFENPIY</i> <i>AQMENEQKESVAATPPSPSLPAKPKPPSRRDPTPTYSATEDTFKDTANLVK</i> <i>EDSEV</i>	232
LRP5	<i>SAIGPVIGIILSLFVMGGVYFVCQRVVCQRYAGANGPFPHEVYVSGTPHVPLNFIAPGG</i> <i>SQHGPFTGIACGKSMSSVSLMGGRRGVPLYDRNHVTGASSSSSSSTKATLYPPIL</i> <i>NPPSPATDPISLYNMDMFYSSNIPATARPYPYIIRGMAPPPTPCSTDVDCSDYSAS</i> <i>RWKASKYYLDLNSDSDPYPPPTPHSQYLSAEDSCPPSPATERSYFHLFPPPSPT</i> <i>DSS</i>	231
LRP6	<i>TNTVGSVIGVIVTIFVSGTVYFICQRMLCPRMKGDGETMTNDYVHGPASVPLGYVPH</i> <i>PSSLSGSLPGMSRGSIMISSLSIMGGSSGPPYDRAHVTGASSSSSSSTKGTYPAILN</i> <i>PPSPATERSHYTMEFGYSSNSPSTHRSYSYRPSYRHFAPPTPCSTDVDCSDYA</i> <i>PSRRMTSVATAKGYTSDLNYDSEPVPPPTPRSQYLSAENYESCPSPYTERSYSH</i> <i>HLYPPPSPTDSS</i>	243

Figure 2 Transmembrane and cytoplasmic regions of LDLR-family receptors. The amino-acid sequences and lengths of the transmembrane (italics) and cytoplasmic regions of the members of LDLR family that undergo proteolytic processing. Phosphorylation motifs (ser/thr) and interaction with intracellular proteins (Table 1) are highlighted: NPXY (red), PPPSP (purple) and the motif recognized by PDZ domains (orange). The spliced isoform ApoER2Δpro does not have the proline-rich region (underlined) that confers on ApoER2 the ability to interact with multiple adaptors (I).

The intracellular region of LRP1 is made up of 100 amino acids (Fig. 2) and contains two NPXY motifs and two dileucine, which interact with intracellular proteins. The NPXY motif was first identified in the LDL receptor, where it is essential for clathrin-mediated internalization (Bansal and Gierasch, 1991). The proximal NPXY motif in LRP1 binds to sorting nexin 17 (SNX17) and is involved in receptor recycling (van Kerkhof et al., 2005). The distal NPXY motif shares the Y residue with the YATL motif that is involved in rapid clathrin-dependent internalization (Li et al., 2000a). This last motif has been implicated in the interaction with phosphotyrosine binding (PTB) domain-containing intracellular signaling proteins such as Disabled 1 (Dab1) (Trommsdorff et al., 1998) and the APP adaptor Fe65 (discussed below) (Pietrzik et al., 2004), among several others (Table 1). In addition, this motif is tyrosine phosphorylated in response to stimulation with platelet-derived growth factor (PDGF) (Boucher et al., 2002; Loukinova et al., 2002),

connective tissue growth factor (CTGF) (Yang et al., 2004) and in v-Src transformed mouse fibroblasts (Barnes et al., 2003). Phosphorylation of the distal NPXY motif would facilitate the phosphorylation of the proximal NPXY motif (Betts et al., 2008), affecting the receptor's interaction with cytosolic proteins (Guttman et al., 2009).

The expression of LRP1 in the liver allows the clearance of various proteins that are present in the plasma. In liver tissue, LRP1 is the key receptor of α2M, facilitating its endocytosis with proteases that are attached to it. Furthermore, LRP1 allows plasma clearance of serine protease inhibitors (Nykjaer et al., 1992; Kounnas et al., 1996; Kasza et al., 1997), clotting factor VIII (Lenting et al., 1999; Saenko et al., 1999; Bovenschen et al., 2005), chylomicron remnants (Rohmann et al., 1998) and matrix metalloproteinases (MMPs) (Emonard et al., 2005). In atherosclerotic dysfunction, LRP1 plays a protective role that is associated with its expression in vascular smooth muscle cells (Boucher et al.,

2003), liver (Espirito Santo et al., 2004), macrophages (Hu et al., 2006; Overton et al., 2007) and adipocytes (Hofmann et al., 2007). For example, in vascular smooth muscle cells, LRP1 expression decreases the activation of the signaling pathway that is triggered by PDGF (Boucher et al., 2003), which normally stimulates the secretion of extracellular matrix proteins (Pompili et al., 1995) and blood vessel wall thickening after damage (Abe et al., 1997).

The BBB regulates the passage of molecules into the central nervous system. The permeability of the BBB can be upregulated in hypoxic conditions (Baker et al., 1971; Garcia et al., 1978). tPA and apolipoprotein E, regulate the permeability of the BBB in a LRP1-dependent manner (Nishitsuji et al., 2011; Yepes et al., 2003). LRP1 plays an important role in neurons because it promotes long-term potentiation (LTP) and either survival (Fuentelba et al., 2009) or apoptosis (Hashimoto et al., 2000; An et al., 2008). In addition, LRP1 interacts with APP (Kounnas et al., 1995; Knauer et al., 1996; Pietrzik et al., 2004) promoting the amyloidogenic pathway (Ulery et al., 2000; Pietrzik et al., 2002). This effect is also seen *in vivo* in LRP1-overexpressing PDAPP mice (model of AD), which exhibit an increased generation of soluble A β and memory deficits (Zerbinatti et al., 2004; Bu et al., 2006).

During cell migration, the remodeling of the cytoskeleton and the extracellular matrix is necessary and involves changes in membrane protease content, such as MMPs. There is evidence showing that the participation of LRP1 in cell migration involves its ability to internalize proteases and protease inhibitors (Yang et al., 2001; Emonard et al., 2004; Emonard et al., 2005) and to regulate their expression (Fayard et al., 2009; Song et al., 2009; Jung et al., 2010). In addition LRP1 signaling (Orr et al., 2002; Orr et al., 2003; Zhu and Hui, 2003; Barker et al., 2004) and the ability of LRP1 to stabilize integrins (Czekay et al., 2003; Salicioni et al., 2003) are involved in cell migration. LRP1 is a calreticulin co-receptor that interacts with the extracellular matrix protein thrombospondin-1, which is known for its anti-adhesive properties (Murphy-Ullrich and Höök, 1989; Greenwood and Murphy-Ullrich, 1998). This interaction activates a trimeric G protein-dependent signal transduction pathway that induces reorganization of the actin cytoskeleton, which leads to focal adhesion disassembly and the stimulation of cell motility (Orr et al., 2002, 2003; Barker et al., 2004). The interaction between LRP1 and its ligands tPA, uPA and plasminogen activator inhibitor-1 (PAI-1) (Bu et al., 1992b, 1993, 1994) is associated with the migration of cells, such as smooth muscle cells (Okada et al., 1996) and mouse embryonic fibroblasts (MEF) (Okada et al., 1996; Weaver et al., 1997). Given the importance of LRP1 in cell migration, it has also been associated with cancer cells (Li et al., 1997, 1998a, 2000; Chazaud et al., 2002; Li et al., 2002; Dedieu et al., 2008; Song and Bu, 2009), where LRP1 interacts with several extracellular matrix proteases that regulate its clearance (Selvais et al., 2011) and expression (Song et al., 2009). Proteolytic

processing of the receptor (discussed below) regulates all of these processes (Selvais et al., 2011).

LRP1 plays an important role in inflammation and phagocytosis, increasing the activity of phagocytes and allowing the ingestion of apoptotic cells (Ogden et al., 2001; Vandivier et al., 2002; Gardai et al., 2005). Using the same mechanism, LRP1 facilitates the removal of degraded myelin that is present in the extracellular medium (Gaultier et al., 2009). The association of LRP1 with the innate immune response (Binder et al., 2000; Basu et al., 2001; Cao et al., 2006; Lillis et al., 2008) is also evidenced as a receptor for heat-shock proteins (Binder et al., 2000; Basu et al., 2001; Binder and Srivastava, 2004; Facciponte et al., 2005), viral peptides (Congote, 2007), and the clearance of apoptotic debris (Tarr and Eggleton, 2005).

Regulation of LRP1 shedding and the role of sLRP1

During its biosynthesis and trafficking, LRP1 is processed by furin, which generates two non-covalently bound subunits, a 515 kDa (α) subunit and a membrane-bound 85 kDa subunit, which is also known as the β -subunit (Willnow et al., 1996b). The first evidence that indicated LRP1 shedding was the identification of a soluble LRP1 fragment (sLRP1) in plasma (Quinn et al., 1997). Interestingly, this fragment was associated with ligands, such as α 2M, tPA, PAI-1 and the ER chaperone RAP. Among the LRP1 fragments, were a 500 kDa furin-processed fragment and a 67 kDa, which corresponds to part of the 85 kDa β -chain. In the human choriocarcinoma cell line BeWo, sLRP1 is detected after 2 h following a metabolic pulse of 35 S-methionine. In these cells this fragment is shed and is produced at the plasma membrane by a process that is not stimulated by phorbol esters but is blocked by metalloproteinases inhibitors (Quinn et al., 1999). Interestingly, sLRP1 is composed of α -chain that is non-covalently bound to a portion of the extracellular part of the β -chain (Quinn et al., 1999). Therefore, similar to Notch processing, the furin-mediated first cut probably precedes the second and possibly regulatory processing step. LRP1 processing is induced by PKC activators (PMA) (May et al., 2002), which occurs with other proteins that undergo shedding (Caporaso et al., 1992; Garton et al., 2001; Kanning et al., 2003). PKC-induced shedding is not related to the phosphorylation of LRP1 itself, and this activity is likely to directly or indirectly activate metalloproteinases of the ADAM family (Merlos-Suárez et al., 2001; Jacobsen et al., 2010; Killock and Ivetić, 2010).

There is evidence indicating that ADAM 10 and 17 are involved in the generation of sLRP1 and that this fragment is present in the brain and cerebral spinal fluid of older patients, suggesting that clearance of the fragment is impaired and/or its production is increased (Liu et al., 2009). The addition of A β peptide to cells expressing LRP1 *in vitro* increases shedding of the receptor and suggests that in AD and older patients, the reduction of total LRP1 could be due in part to an

increase in processing (Liu et al., 2009).

Concordant with LRP1 participation in innate immunity and inflammation (Binder et al., 2000; Basu et al., 2001; Cao et al., 2006; Lillis et al., 2008), both lipopolysaccharide (LPS) - and interferon- γ -induced LRP1 shedding from the β -chain (Gorovoy et al., 2010) releases sLRP1 and produces a 25 kDa CTF (Zurhove et al., 2008). This effect is seen *in vitro* in cultured macrophages cell lines and *in vivo* in mice (Gorovoy et al., 2010). LPS activates Toll-like receptor 4 (Miller et al., 2005) and triggers PKC-mediated ADAM 17 activation (Gorovoy et al., 2010). Increased levels of sLRP1 are seen in plasma from patients with rheumatoid arthritis and systemic lupus erythematosus. Purified sLRP1 from human plasma activates signaling pathways, such as p38 MAPK and JNK in macrophage cell lines, and sLRP1 transiently activates the NF κ B pathway and the expression of inflammatory cytokines, such as TNF- α and IL-10 (Gorovoy et al., 2010). This activation indicates that soluble fragments may be relevant in cell-to-cell communication (Fig. 3) that in the case of sLRP1 potentiates LPS-induced inflammatory responses. In contrast to the inflammatory role of sLRP1 in macrophages, injured sciatic nerve from mice exhibit an increase in the shedding of LRP1, but in this case the

sLRP1 α has anti-inflammatory properties, decreasing TNF α expression and p38 activation (Gaultier et al., 2008). Interestingly, a control mechanism that is dependent on the production of LRP1-ICD and γ -secretase activity is important for limiting the inflammatory response. LRP1-ICD binds to the interferon regulatory factor 3, promoting its degradation and reducing the expression of inflammatory genes (Zurhove et al., 2008).

As previously mentioned, among the LRP1 ligands are several proteases and proteases-inhibitors (Herz et al., 1992b; Kounnas et al., 1993; Andreasen et al., 1994; Bu et al., 1994; Herz and Willnow, 1994; Strickland et al., 1995; Kounnas et al., 1996; Stefansson et al., 1996; Knauer et al., 1997), including metalloproteinases (MMPs) such as MMP2, MMP3 and MMP9 (Hahn-Dantona et al., 2001; Yang et al., 2001; Strickland and Ranganathan, 2003; Mantuano et al., 2008) that are degraded after LRP1-mediated internalization. Through the regulation of the availability of these ligands, LRP1 regulates the dynamics of the extracellular matrix, modulating the clearance of proteases and consequently, cell signaling, adhesion and migration. This protease system regulates LRP1 shedding via a feedback mechanism. This observation is particularly interesting for cancer cells




Figure 3 Overview of proteolytic processing. Schematic representation of the proteolytic processing of a membrane protein. Initially, membrane proteins are proteolytically processed and release a soluble extracellular fragment in a process that is called "shedding." Among the proteases that carry out shedding are matrix metalloproteinases, ADAMs and BACE. Next, the protein fragment that remains associated with the membrane is proteolytically processed by the γ -secretase complex and releases a soluble intracellular fragment (ICD). Proteolytic processing can be constitutive, but it can also be regulated by different factors, such as extracellular and intracellular ligands (1) association of the membrane protein with lipid rafts (2) and/or endocytic trafficking (3) the resulting fragments (CTFs and ICDs) may have the ability to signal which may affect various signaling pathways through their interaction with adaptors, or in the case of ICD may migrate to the nucleus, where it can affect gene expression. The soluble fragments can also modulate the availability of some ligands and function, for example, as dominant negative forms of the receptors.

that express high levels of membrane-associated MMPs. MT1-MMP activates MMP2, and this activation correlates with an increase in the invasive capacity of the cancer cells (Seiki, 2003). MT1-,2-,3- and 4-MMPs also induce the shedding of the LRP1 α -chain, avoiding the role of the receptor in the clearance of MMPs (Rozanov et al., 2003). In addition, under conditions that affect pulmonary function, such as in patients suffering from acute respiratory distress syndrome, the increased shedding of LRP1 that is detected by the presence of sLRP1 is associated with high levels of MMP2, MMP9 and laminin in the bronchoalveolar fluids (Wygrecka et al., 2011). This observation indicates that the presence of intact LRP1 is required for the appropriate degradation of these MMPs and the maintenance of the basal membrane. Further more, damage to a blood vessel wall induces an increase in the expression of MT1-MMP, which is related to the dedifferentiation of contractile vascular smooth muscle cells (VSMC) to a proliferative and invasive phenotype and results in vascular disorders and damage. The upregulation of MT1-MMP induces an increase in the proteolytic processing of LRP1, which, together with the PDGF receptor- β (PDGFR- β) pathway, induces a reduction in VSMC contractile proteins and promotes the proliferative phenotype (Lehti et al., 2009).

In other systems, such as the endometrium, LRP1 shedding is likely to be mediated by ADAM12 and is under the control of steroidal hormones. LRP1 mRNA expression is constant during the menstrual cycle; however, LRP1 protein levels decrease because of proteolytic processing. In the presence of progesterone and estradiol, the release of the sLRP1 515-kDa- α -chain and of 55-kDa truncated form of the β -chain subunit is inhibited (Selvais et al., 2009). At the end of the cycle, the hormone levels drop and this reduction activates LRP1 processing. Next, MMP2 and MMP9 accumulate, allowing the detachment of the endometrial layer through menstrual bleeding (Selvais et al., 2009).

The interaction of LRP1 with tPA (Bu et al., 1992a, b; Bu et al., 1993) regulates the systemic degradation of this thrombolytic enzyme. In addition, this interaction promotes LTP in the hippocampus (Zhuo et al., 2000) and increases the synthesis of MMP9 and MMP3 (Wang et al., 2003; Suzuki et al., 2009; Zhang et al., 2009). By regulating the expression of MMPs, LRP1/tPA regulates the BBB permeability and is associated with cerebral bleeding and brain injury (Yepes et al., 2003; Suzuki et al., 2009). tPA is also involved in the processing of LRP1, inducing the release of sLRP1 in cultured astrocytes. This processing would require LRP1 itself because the process is blocked by exogenous RAP. *In vivo*, this processing occurs under conditions of cerebral ischemia and is associated with an increase in detachment astrocytic end-feet processes and edema (Polavarapu et al., 2007). Interestingly, depending on the cells, the interaction of tPA with LRP1 results in the differential activation of AKT; in astrocytes, AKT binds to the cytoplasmic domain of LRP1 and is activated. The phosphorylation of AKT in this case

relates to astrocyte detachment and edema (An et al., 2008). In contrast, the binding of tPA to LRP1 in neurons under hypoxic conditions (experimentally induced by middle cerebral artery occlusion in mice), is related to a decrease in AKT activity (An et al., 2008), neuronal apoptosis, caspase 3-cleavage, and an increase in γ -secretase activity, which correlates with the processing of LRP1-CTF and the translocation of LRP1-ICD to the nucleus (Polavarapu et al., 2008).

Related to its role as a signaling protein and a receptor for extracellular matrix proteins, including the proteases mentioned above, LRP1 participates in cancer. However, the role of LRP1 in this pathology is controversial and appears to be highly dependent on the cell context. As mentioned before, LRP1 regulates the degradation and expression of proteinases, and LRP1 expression has been positively and negatively associated with tumor development and progression (Li et al., 1997; Li et al., 1998b; Li et al., 2000; Chazaud et al., 2002; Li et al., 2002; Dedieu et al., 2008; Song and Bu, 2009). Certain cancer cell lines also manage LRP1 processing differently. For example, in the HT1080 human fibrosarcoma cell line, the association of LRP1 with lipid rafts decreases the production of the soluble β -chain fragment and the release of the intact α -chain in a reaction that is catalyzed by ADAM12 and MT1-MMP (Selvais et al., 2011). HT1080 cells exhibit different phenotypes, an epithelial-like and a fibroblast-like phenotype that differ in their plasma membrane cholesterol content. In the epithelial phenotype, there is less processing of LRP1, and this effect is reversed upon depletion of cholesterol. In contrast, the fibroblast-like cells contain lower levels of plasma membrane cholesterol and accumulate MMP2 and MMP9 in the cell medium along with an increase in LRP1 processing (Selvais et al., 2011). The studies in HT1080 cells indicate that LRP1 plays a protective role against degradation of the extracellular matrix in some cancer cells; however, as a signaling protein, LRP1 also induces the expression of its own ligands MMP2 and MMP9, which correlates with the invasive phenotype of cancer cells (Song et al., 2009). LRP1 binds growth factors, such as PDGF-BB (Loukinova et al., 2002; Boucher et al., 2003) and TGF β (Huang et al., 2003; Tseng et al., 2004), and regulates their corresponding signaling pathways and physiologic functions. Therefore, LRP1 shedding has the potential to interfere with these events, for example, if the sLRP1 binds and sequesters the signaling ligands (Fig. 3).

One published report indicates that LRP1 is processed by BACE (von Arnim et al., 2004), the secretase that processes APP at the β -site, and generates β CTF and s β APP. The interaction between LRP1 and BACE, as demonstrated by co-immunoprecipitation and FRET-FLIM (fluorescence resonance energy transfer - fluorescence lifetime imaging microscopy) experiments, was determined in different cell lines of neuronal origin. Interestingly, this interaction is independent of the LRP1 ectodomain, occurs predominantly in the endosomal compartment and is regulated by cholesterol

levels. *In vitro*, BACE generates a sLRP1 that is derived from the β -chain and a 25 kDa LRP1-CTF. BACE expression correlates with the detection of LRP1-ICD, the product of the second processing step that is mediated by the action of γ -secretase (von Arnim et al., 2004). The physiological relevance of this processing it is unknown.

Gamma-secretase-mediated processing of LRP1-CTF and the role of LRP1-ICD

After LRP1 shedding, the 25 kDa membrane-associated β -chain fragment (LRP1-CTF) is further processed by the γ -secretase complex, thereby producing an intracellular fragment or ICD. The generation of this fragment was first shown and its nuclear translocation was inferred using a reporter gene (luciferase) under the control of the Gal4-Vp16 promoter that was fused to the carboxyl-terminal of the LRP1 tail (May et al., 2002). In addition, the 12 kDa LRP1-ICD that was detected in HEK293 cells expressing LRP1 disappears when the γ -secretase complex is inhibited by DAPT, a γ -secretase inhibitor, and its degradation is controlled by the proteasome (May et al., 2002). *In vivo*, in mice with a middle cerebral artery occlusion (MCAO), it is possible to find nuclear staining for LRP1-ICD in neurons. located in the ischemic area of the brain. The localization of LRP1-ICD in neurons is dependent on γ -secretase activity and on the tPA/LRP1 interaction, and it is related to neuronal apoptosis, suggesting a role for the receptor ICD in this process (Polavarapu et al., 2008) (Fig. 3).

In addition to the examples described here, the functional relevance of the fragments generated after shedding, either the LRP1-CTF or LRP1-ICD, is not evident. One simplistic view is to consider the processing steps of LRP1 to be part of a pathway to down regulate the receptor. Another possibility is to consider the different partners that bind to the LRP1 cytosolic domain and the functions they perform in the cell (Table 1). One of the cytosolic proteins that bind to both NPXY motifs in LRP1 is Fe65 (Pietrzik et al., 2004). Fe65, Fe65L and Fe65L2 are multidomain adaptor proteins that form multiprotein complexes. Fe65 is highly expressed in the nervous system, is involved in neuronal development and FE65/Fe65L double-KO mice have cortical dysplasia (Guénette et al., 2006). Fe65 has three modules that allow it to interact with different proteins and, therefore, determine its multiple functions. Through its PTB domain 1, Fe65 interacts with the NPXY motifs of LRP1 (Trommsdorff et al., 1998; Pietrzik et al., 2004), megalin/LRP2 (Alvira-Botero et al., 2010) and ApoER2 (Hoe et al., 2006a) (Table 1) and to the transcription factors CP2/LSF/LBP1 (Zambrano et al., 1998) and Tip60 (Cao and Südhof, 2001). FE65 interacts with APP through its PTB2 domain and with MENA (mammalian homolog of *Drosophila*-enabled) and the nucleosome assembly factor SET (McLoughlin and Miller, 2008) through its WW domain. Therefore, the function of Fe65 is related to gene expression regulation, cell migration and neuronal

growth cone formation. The overexpression of Fe65L1 drives the LRP1 receptor to the degradation pathway (Guénette et al., 2002). Regarding the function of the LRP1 fragments, the binding of LRP1-CTF to Fe65 through its second NPXY motif could regulate APP processing (Pietrzik et al., 2002). The LRP1-ICD fragment could regulate the AICD-mediated Fe65 activation of transcriptional activity (Yang et al., 2006) and/or because LRP1 binds to the same PTB domain as Tip60 and CP2/LSF, LRP1-ICD may affect the intrinsic transcriptional activity of Fe65.

Megalyn/LRP2, a scavenger receptor with relevant physiologic roles

Tissue expression and the roles of megalin/LRP2

Megalyn/LRP2 is a 600 kDa glycoprotein that acts mainly at the cell surface as an endocytic receptor for several ligands (Barth and Argraves, 2001; Marzolo and Farfán, 2011; Moestrup and Verroust, 2001). Megalin is composed of a large extracellular domain consisting of four cysteine-rich complement-type ligand binding repeats that are separated by β -propeller domains (Saito et al., 1994) made up of YWTD repeats that are flanked by EGF-like modules (Fig. 1). In addition, megalin contains one transmembrane domain that allows the receptor to associate with membrane domains that are rich in cholesterol and glycosphingolipids (Marzolo et al., 2003) and to be a substrate for the γ -secretase complex (Zou et al., 2004; Biemesderfer, 2006) (see below). Human megalin contains a 209-amino-acid cytoplasmic domain that has motifs that regulate receptor trafficking and function. Among the cytoplasmic motifs are three NPXY motifs that are important for receptor internalization and binding to adaptors, such as Dab2 (Oleinikov et al., 2000; Morris et al., 2002b; Gallagher et al., 2004), ARH (Nagai et al., 2003) and signaling proteins (May et al., 2003a). The cytoplasmic tail of megalin contains two proline-rich sequences and a PDZ binding motif that are responsible for the receptor's interaction with scaffold and signaling proteins, such as GIPC/synectin, megalin-binding protein (MegBP), ANKRA, myosin VI, SKIP, Dab2, APPL1 and GSK3 (Rader et al., 2000; Patrie et al., 2001; Lou et al., 2002; Larsson et al., 2003; Petersen et al., 2003; Naccache et al., 2006; Erdmann et al., 2007; Marzolo and Farfán, 2011) (Table 1). Megalin is unique among the receptors of the LRP family (with the exception of the receptors LRP5 and 6, see below), in that it is constitutively phosphorylated by GSK3 on a PPPSP motif in a distal proline-rich domain of its cytoplasmic tail (Yuseff et al., 2007). The PPPSP motif and the PDZ binding motif are conserved in megalin receptors from different species (Marzolo and Farfán, 2011) (Fig. 2).

Megalyn is predominantly expressed in epithelial tissues, specifically at the apical surface of the epithelial cell (Cui et al., 1996; Morales et al., 1996; Willnow et al., 1996a;

Nielsen et al., 1998; Zheng et al., 1998; Hermo et al., 1999; Mizuta et al., 1999; Marzolo et al., 2003). During development, megalin is expressed in the neuroepithelium (Willnow et al., 1996a; Spoelgen et al., 2005) and in a subpopulation of neural progenitors in the spinal cord of embryonic mouse (Wicher et al., 2005). In the adult nervous system, the receptor is located in the choroid plexus (Chun et al., 1999; Carro et al., 2005), in the ependymal cells of the lateral ventricles (Gajera et al., 2010) and in the spinal cord (Wicher et al., 2006). In addition, the retinal ganglion cells (Fitzgerald et al., 2007), cerebellar granule neurons (Ambjørn et al., 2008), the inner ear (Mizuta et al., 1999; König et al., 2007) and the eye (Lundgren et al., 1997; Assémat et al., 2005; Fisher and Howie, 2006) express megalin. At the periphery, megalin is present in several organs, including the kidney, lung, thyroid (Willnow et al., 1996a; Lundgren et al., 1997; Marinò et al., 1999), epididymis (Hermo et al., 1999), mammary gland (Lundgren et al., 1997; Rowling et al., 2006) and gallbladder (Erranz et al., 2004; Tsaroucha et al., 2008).

The physiologic functions of megalin have been determined using different animal models that are deficient in this receptor (Lehste et al., 1999; Willnow et al., 1996a; Lehste et al., 2003; Rubera et al., 2004; Spoelgen et al., 2005; Gajera et al., 2010). Megalin KO mice exhibit a very low survival rate (1 in 50), because they die immediately after birth from respiratory insufficiency (Willnow et al., 1996a). A physiologically critical role for megalin is in the kidney, where it mediates the recapture of filtered molecules in the proximal tubule (PT) (Cui et al., 1996; Christensen et al., 1998; Moestrup et al., 1998; Christensen et al., 1999; Lehste et al., 1999; Lehste et al., 2003). Megalin also plays a role in the recapture of lysosomal enzymes and lysosomal biogenesis (Nielsen et al., 2007). The KO mice for this receptor exhibits ultrastructural abnormalities in the endosomal compartments of PT epithelial cells, including the absence of apical recycling endosomes, dense tubules and other endocytic structures, such as clathrin coated pits and vesicles (Lehste et al., 1999). In addition, the KO mice exhibit several malformations in their brains, which is a syndrome known as holoprosencephaly (Willnow et al., 1996a). Because of its function as a receptor for signaling proteins and morphogens, such as BMP4 and Shh (McCarthy et al., 2002; Spoelgen et al., 2005), the receptor is relevant in the development of the ventral telencephalon and of the mouse spinal cord (Wicher and Altskogius, 2008). The role of megalin in controlling BMP4 levels and activity has a consequence in adult brain neurogenesis (Gajera et al., 2010). The expression of megalin in the central and peripheral nervous systems and its ability to bind ligands, such as metallothionein (Klassen et al., 2004; Wolff et al., 2006; Fitzgerald et al., 2007; Ambjørn et al., 2008; Chung et al., 2008; Pedersen et al., 2010;) and transthyretin (Fleming et al., 2009), suggest that the receptor is involved in processes of neuronal survival and regeneration.

Megalin binds and internalizes several ligands, promoting

their degradation or recovery (Marzolo and Farfán, 2011). Among these ligands are apolipoproteins (Hammad et al., 2000; Christoffersen et al., 2006), albumin (Cui et al., 1996), vitamin D, B12 and A complexes with their corresponding vitamin binding proteins (Christensen et al., 1999) and signaling molecules, such as angiotensin II and (1-7) (Gonzalez-Villalobos et al., 2004; Gonzalez-Villalobos et al., 2005), leptin (Hama et al., 2004), clusterin/apoJ (Zlokovic et al., 1996; Hammad et al., 1997) and insulin (Orlando et al., 1998). The renal functions associated with these ligands are crucial for understanding the phenotype of the megalin knockout mice, which suffer from extensive proteinuria and rickets (Nykjaer et al., 1999; Lehste et al., 2003). In humans, many pathology-associated conditions, including diabetic nephropathy, hypertension and genetic diseases, such as Dent disease and Lowe Syndrome, exhibit megalin dysfunctions (Marzolo and Farfán, 2011).

Evidence of megalin/LRP2 processing

The expression of megalin in the kidney and its presence in the urine indicate the possibility of proteolytic processing. In the early 1990s, Birk and colleagues (Birk et al., 1991) found a high molecular weight hydrophobic polypeptide in urine, which they thereafter identified as megalin. This protein was shed, along with other membrane proteins from the proximal tubule (PT) from different areas of the brush border. Using antibodies against the N-terminal or the C-terminal of megalin, the full-length receptor was shown to be at the base of the microvilli and in the coated pit regions. Truncated forms of megalin, detected only by N-terminal antibodies, are present in the areas where the full-length protein is present and over the microvilli (Bachinsky et al., 1993). The presence of soluble megalin in the urine is common but in conditions such as Lowe Syndrome, in which patients exhibit proteinuria, there is a significant reduction of megalin in the urine (Norden et al., 2002), thereby suggesting that the recycling and/or the processing of the protein is affected. Megalin studies using primary cultured PTCs have been difficult because the expression of the receptor is progressively lost. Some PT cell lines express megalin, and indications of megalin processing have been found in these cells. In a rat-derived PT cell line, IRPT, an antibody that recognizes the amino-terminal of megalin but not its carboxyl-terminal, detects fragments of approximately 200 and 400 kDa in the culture medium. The full-length megalin protein is detected in the cell lysate by the antibody that recognizes the carboxyl-terminal of the receptor (Jung et al., 1998). The *in vivo* and *in vitro* evidence indicates that megalin undergoes proteolytic processing and has prompted the investigation of the mechanisms and roles of this proteolytic processing using different PTCs. The incubation of opossum kidney proximal tubule (OKP) cells with PKC stimulators, which have been linked to the activation of α -secretase, results in the generation of 35–40 kDa megalin fragments that are recog-

nized by an antibody against the carboxy-terminal domain of the receptor. Similar results are obtained when the γ -secretase complex is inhibited, demonstrating that megalin also undergoes RIP (Zou et al., 2004).

Megalín processing has a constitutive component; however, although many of its ligands, such as insulin, angiotensin, sonic hedgehog and BMP, activate their own signaling receptors, it is not known which ligands also regulate megalín processing. There is evidence that the insulin-signaling pathway activates ADAM 10 and 17 metalloproteinases in kidney cells, stimulating the shedding of the type I membrane protein Klotho (Chen et al., 2007). Interestingly, some Klotho functions overlap with and/or antagonize megalín functions, for example, the homeostasis of vitamin D, calcium and phosphate (Lanske and Razzaque, 2007; Kuro-o, 2008). To be precise, 25-OH vitamin D enters PTC as a complex with the vitamin D-binding protein (DBP), through megalín endocytosis (Nykjaer et al., 1999), thereby allowing the activation to 1,25-(OH)₂ Vitamin D by the enzyme 1 α -hydroxylase (CYP27B1). Adding DBP to OKP cells induces a low level of megalín CTF-accumulation (MCTF), suggesting that this ligand may regulate megalín processing (Zou et al., 2004). Therefore, it is plausible that similar or related mechanisms or ligands (for example, insulin and/or DBP) control megalín and Klotho proteolysis.

In contrast to the known roles for the Notch and APP ICDs, a role for the final product generated by proteolytic processing has been difficult to determine for the LDLR family, partly because it is difficult to detect this cytosolic fragment. In the case of megalín, cytoplasmic domain fragments of 30 kDa and 35–40 kDa, possibly corresponding to MICD and MCTF, respectively, have been found in LLC-PK1 epithelial cells (a PTC derived from pig) and non-epithelial cells (spinal cord oligodendrocytes from mouse) both in the nucleus and in membrane fractions (Wicher et al., 2006). Additionally, nuclear staining of megalín has been shown in primary cultures of human gallbladder epithelial cells using an antibody that recognizes the cytoplasmic domain of the receptor (Marzolo and Farfán, 2011). Indeed, many megalín fragments are detected in extracts of gallbladder epithelial cells (Erranz et al., 2004), suggesting the active proteolytic processing of the receptor in this tissue.

A putative role for MICD has been examined in cell culture (Li et al., 2008) and in transgenic mice (Christ et al., 2010), and the results have been controversial. When MCTF or MICD is expressed in OKP cells the endogenous expression of megalín and of the sodium-proton Exchange protein 3 (NHE3) decreases. This reduction is not observed when γ -secretase is blocked, suggesting that MICD mediates the inhibition of megalín and NHE3 expression. In addition, MCTF processing takes place in the endosomal compartment (Li et al., 2008). In this work, the detection of a double-tagged MICD was not possible in transfected cells, and the analysis was carried out using an antibody that recognizes the cytoplasmic domain of the receptor, which does not

distinguish the endogenous megalín from the transfected MCTF and MICD receptor fragments. Conversely, a possible role for MICD in the *in vivo* regulation of megalín expression and function in the kidney was analyzed in a transgenic model mouse expressing one megalín and one MICD allele (Christ et al., 2010). In these animals, megalín protein levels were unchanged, and the endocytic function of renal PT was similar to the control animals. However, it is important to note that the construct used in this report contained three Flag epitopes that could affect the nuclear expression of MICD, which was not detected in the nuclei of the PT cells. The nuclear presence of MICD is considered important for this fragment to play a role in the regulation of gene expression, as has been determined for other proteins that experience proteolytic processing, such as Notch (Fortini, 2002).

The roles of MCTF and MICD are potentially related to the functions of proteins that associate with the cytoplasmic domain of megalín (Table 1). As mentioned above, several adaptor proteins that regulate membrane trafficking, cytoskeleton association and/or signaling, including Dab2, APPL1, GSK3, GIPC, MegBP and AKT (Caruso-Neves et al., 2006), recognize and bind motifs in the cytoplasmic tail of megalín. For example, Dab2 is an endocytic adaptor protein that mediates the clathrin dependent internalization of LDLR and ApoER2 (Cuitino et al., 2005; Morris and Cooper, 2001), which interacts with myosin VI and with the actin cytoskeleton (Morris et al., 2002a). Dab2 is a signaling protein because it plays a role in the activation of the TGF β signaling pathway (Hocevar et al., 2001) and in the inhibition of the canonical Wnt-signaling pathway (Hocevar et al., 2003). This adaptor protein plays a role in development (Morris et al., 2002b; Yang et al., 2007) and in cancer, where it acts as a tumor suppressor protein (Xu et al., 1998; Zhou and Hsieh, 2001), and there is evidence suggesting that it can translocate to the nucleus (Cho et al., 2000). Conversely, APPL1 is a signaling protein that associates with endosomes and regulates several signaling pathways including those for neurotrophins through TrkA (Lin et al., 2006), EGFR (Miaczynska et al., 2004) and adiponectin (Mao et al., 2006). APPL1 is found in the nucleus, where it is thought to act as a transcription regulator (Pilecka et al., 2007). The activity of these adaptor proteins could be regulated by the localization of the megalín fragment, i.e., in the plasma membrane or endosome for MCTF and in the cytosolic or nuclear fraction for MICD, and this, in turn, may regulate trafficking and other physiologically important signaling pathways (Fig. 3).

ApoER2, a signaling receptor with an essential role in the CNS

Functional characteristics of ApoER2

ApoER2 is a type I membrane protein (Fig. 1) that is

expressed in neurons, during CNS development and in adult neurons, placenta, endothelial cells, platelets and certain epithelial tissues, such as the choroid plexus, the epididymis and enterocytes (Kim et al., 1996; Novak et al., 1996; Stockinger et al., 1998; Riddell et al., 1999; García-Miranda et al., 2010). Considering that LDLR knockout mice exhibit normal cholesterol homeostasis in the brain (Osono et al., 1995), it was initially thought that ApoER2 participated in SNC cholesterol lipoprotein homeostasis. However, later studies showed that the main function of this receptor is to trigger a signal transduction pathway following binding of reelin (Darcangelo et al., 1999), which is an extracellular matrix protein that is secreted in the developing brain and in the adult brain (Ogawa et al., 1995; Del Río et al., 1997; Bar and Goffinet, 1999). Along with VLDLR, another member of the LDLR family that binds reelin, ApoER2/reelin participates in brain development by regulating neuronal migration and correct positioning in the cortex, the hippocampus and the cerebellum (Hiesberger et al., 1999; Trommsdorff et al., 1999). These features of brain development are significantly altered in VLDLR/ApoER2 double-knockout mice (Trommsdorff et al., 1999), which is similar to the phenotype of reelin-deficient mice (Ogawa et al., 1995; Ogawa, 2000).

The ApoER2/reelin system also plays a role in synaptic plasticity, dendritic branching, maturation and surface expression of NMDA-R, neuronal survival, neurogenesis in the adult brain and in neuroregeneration (Beffert et al., 2005; Beffert et al., 2006; Pujadas et al., 2010). ApoER2 is expressed as several splice variants, one of which includes exon 18 that allows the expression of a 59-amino-acid insertion in the cytoplasmic domain of the human receptor (Fig. 2). This variant is not required for the role of reelin during development, but it is required for reelin-mediated activation and tyrosine-phosphorylation of NMDA-R and LTP stimulation (Beffert et al., 2005, 2006; Hoe et al., 2006b). ApoER2 knockout mice exhibit a long delay in the late phase of the LTP, which is related to the stability and maintenance of synapses in the central nervous system (Weeber et al., 2002).

Reelin binding to ApoER2 induces the recruitment of the Dab1 adaptor protein to the endocytic NPXY motif in the receptor, where it is phosphorylated by the SRC-family kinase Fyn (Keshvara et al., 2001; Arnaud et al., 2003; Ballif et al., 2003; Bock and Herz, 2003; Beffert et al., 2006). SRCs are activated by reelin following binding to plasma membrane ephrins type b (Sentürk et al., 2011). Following Dab1 phosphorylation (Rice et al., 1998), ApoER2/reelin activates a variety of proteins that are involved in different signaling pathways, including PI3K (Bock et al., 2003), LimK1 and n-cofilin that are involved in the leading processes of migrating neurons (Chai et al., 2009a, 2009b), and CRKL and the small GTPase Rap1 (Ballif et al., 2004), which induce actin cytoskeleton rearrangements.

ApoER2 proteolytic processing and its relationship with receptor trafficking and signaling

The first evidence indicating that ApoER2 experiences proteolytic processing came from the studies of Herz's group. (May et al., 2003b). ApoER2, which is present in hippocampal neurons in embryonic rat brains, was found as a full-length protein and as two smaller 25 kDa and 18 kDa fragments corresponding to the CTFs of the two differentially spliced variants of the receptor, with the larger one containing the 59-amino-acid cytoplasmic domain insert (May et al., 2003b). Interestingly, when ApoER2-expressing cells are treated with DAPT, the CTFs levels increase (May et al., 2003b; Hoe and Rebeck, 2005; Fuentealba et al., 2007), indicating that γ -secretase is responsible for the ApoER2-CTF RIP that produces the corresponding intracellular domain or ICD. In contrast, the α -secretase protein inhibitor TIMP3 decreases the level of ApoER2-soluble extracellular fragments and CTFs, thereby suggesting an active role for α -secretase in the first step of ApoER2 processing at the plasma membrane (Hoe et al., 2007).

As discussed for the other LDLR family receptors, it is important to assign a functional role for proteolytic processing of the receptors and to determine how processing is regulated. Many studies have demonstrated the regulatory roles of extracellular ligands and intracellular inter-actors in ApoER2 processing. ApoE, F-spondin, reelin and APP are extracellular ligands for ApoER2 (Hoe and Rebeck, 2005; Hoe et al., 2005; Hoe et al., 2006c; Fuentealba et al., 2007). Each of these ligands induces the accumulation of the receptor CTF, which is an indication of ectodomain shedding (Hoe and Rebeck, 2005; Hoe et al., 2005, 2006c). F-spondin is an extracellular matrix protein that is involved in neuronal development (Higashijima et al., 1997; Feinstein et al., 1999; Young et al., 2004) and regeneration (Burstyn-Cohen et al., 1998). This ligand binds to ApoER2 and APP, linking them at the membrane, which results in a decrease in the APP amyloidogenic processing that generates A β and causes an increase in the amount of APP fragment processed by α -secretase (Hoe et al., 2005). Reelin also stimulates ApoER2 processing (Hoe et al., 2006c; Duit et al., 2010). However, the mechanism involved in the induction of ApoER2 processing is not dependent on the signaling pathway induced by reelin, as demonstrated by experiments using COS7 and 3T3 fibroblasts that lack endogenous expression of the crucial signaling protein Dab1 (Hoe and Rebeck, 2005; Duit et al., 2010). An alternate possibility is that this ApoER2 processing occurs following ligand-induced receptor clustering that promotes ApoER2 association to lipid rafts (see below).

A number of adaptor proteins bind to the ApoER2 cytoplasmic domain and regulate its trafficking and signaling (Table 1). Some of these proteins, including JIP1/2 (Stockinger et al., 2000), PSD95 (Herz and Chen, 2006) and the adaptor protein X11 α / β Mint (He et al., 2007), bind to the exon 19-variant of ApoER2, specifically to the insert encoded

by exon 18 in human ApoER2. Similar to other members of the receptor family, ApoER2 is internalized by a clathrin-mediated pathway that depends on the integrity of its unique NPXY motif and on the presence of the adaptor protein Dab2 (Cuitino et al., 2005). Other adaptors, including the signaling proteins Dab1 and Fe65, also bind to NPXY (Hoe et al., 2006a; Hoe et al., 2006c; Marzolo and Bu, 2009).

The analysis of Dab1 is interesting in that its function is related to the signaling pathway triggered by reelin, but it also has the potential to block ApoER2 internalization. On the other hand, Dab1 also binds to the distal NPXY motif in the cytosolic tail of LRP1 (Trommsdorff et al., 1998) and to the NPXY motif of APP (Homayouni et al., 1999), and it interacts directly with Fe65 to destabilize the FE65-mediated APP and LRP1 complex (Kwon et al., 2010). Considering its association to ApoER2, Dab1 may play a role in the receptor processing. In the absence of reelin, the overexpression of Dab1 increases the surface level and processing of ApoER2 and APP (Hoe et al., 2006c), resulting in an increase in the α -secretase processing of APP and the production of ApoER2-CTF. Therefore, as discussed previously, the extracellular ligand (reelin) alone or overexpression of the critical intracellular signaling adaptor (Dab1) alone induces the receptor processing. However, the possibility that the reelin signaling pathway regulates processing is still an open question of more physiologic relevance. If the different signaling pathways that are activated by this ligand are considered (see section "Functional characteristics of ApoER2"), reelin could also regulate the proteolytic processing mediated by ADAMs (Box1). It has been shown that the kinase Fyn, which is activated in the reelin pathway and phosphorylates Dab1 (Arnaud et al., 2003) and ApoER2 (Hoe et al., 2008), also affects the trafficking and processing of the receptor. Even in cells that lack Dab1 and express a constitutively active form of Fyn, ApoER2 accumulates at the cell surface, and there is an increase in the production of the receptor CTF. *In vivo*, in Fyn-KO mice, there is a reduction in ApoER2-CTF and the appearances of a smaller of 20 kDa fragment that could represent the isoform that lacks the 59-amino-acid insert (Hoe et al., 2008).

Another adaptor that binds to the ApoER2 endocytic motif is Fe65 (Hoe et al., 2006a). *In vitro*, the overexpression of FE65 is linked to an increase in the cell surface level and processing of ApoER2, which is reflected in the accumulation of the receptor's CTF and the secretion of its soluble ectodomain (sApoER2). These observations probably explain why Fe65 KO mice exhibit a decreased processing of ApoER2 (Hoe et al., 2006a). It is unclear if the ICD of ApoER2 interacts with FE65 in the nucleus; indeed, there is no evidence showing the presence of this fragment in the nucleus, although in an artificial system when the receptor was fused to Gal4, translocation of the ApoER2 cytoplasmic domain to the nucleus was inferred (May et al., 2003b).

The overexpression of many of the adaptor proteins that bind to the ApoER2 tail in transfected cell lines expressing

the receptor or in hippocampal neurons shows that almost all of them stimulate receptor shedding but simultaneously increase receptor levels at the cell surface. At first glance, these results suggest that processing requires the receptor to be present at the plasma membrane. Thus, by competing with the endocytic machinery, the adaptor proteins binding to the NPXY motif would indirectly stimulate processing in a manner that does not decrease the cell surface expression of the receptor. However, the expression of a receptor containing a mutated NPXY motif that normally stays longer at the cell surface (Cuitino et al., 2005) but is unable to recruit Dab1 and Fe65 does not show an increase in its processing (Hoe et al., 2006c). This finding indicates that the mere presence of ApoER2 at the cell surface is not sufficient to trigger its processing. Indeed, it is not completely clear where the different processing steps take place in the receptor's intracellular itinerary (Fig. 3).

An significant proportion of ApoER2 resides in cholesterol- and glycosphingolipid- rich membrane domains or lipid rafts (Riddell et al., 2001; Cuitino et al., 2005), and this property is probably due to the O-glycosylation that some variants of the receptor exhibit (Duit et al., 2010); however, receptor internalization is not altered when lipid rafts are affected (Cuitino et al., 2005). Following reelin binding, ApoER2 is internalized using the clathrin-mediated pathway and enters the lysosomal degradation pathway. In contrast, a VLDLR isoform that lacks O-glycosylation and does not associate with lipid rafts recycles to the plasma membrane following reelin signaling and internalization (Duit et al., 2010). In ApoER2 proteolytic processing, the role of O-glycosylation and raft association is still unclear. The first report showing ApoER2 processing indicated that the O-glycosylation was associated with an inhibition of this process (May et al., 2003b). However, a recent report using different chimeric receptors containing either the O-glycosylated ApoER2 ectodomain or the VLDLR ectodomain that lacks O-glycosylation, suggests that O-glycosylation and lipid raft association increase the processing of ApoER2 (Duit et al., 2010), which is a phenomenon that is not detected in the VLDLR isoform that lacks O-glycosylation. The authors suggest that γ -secretase resides in lipid rafts, and this possibility would explain in part the preferential processing toward the lipidraft-associated proteins. However, the γ -secretase complex normally cuts its substrates (the receptor CTF in this case) once they are generated and it is the first cut, mediated by metalloproteinases, that is regulated. If we consider the published literature, there is no evidence suggesting that ApoER2 is processed by BACE, which is an enzyme that resides in lipid rafts; most of the evidence indicates that the first cut, or shedding, is mediated by α -secretases which are more frequently found excluded from rafts. Other problems with the conclusions of Duit et al. include that they did not study the ApoER2 isoform that naturally lacks the O-glycosylation domain and the VLDLR that naturally contains this domain to establish that

O-glycosylation, lipid rafts association and proteolytic processing are linked events.

The proteolytic processing of the receptor could be of physiologic relevance; however, it is still not completely clear if this is true. Nevertheless, in the case of one of the splice variants of the receptor that includes a furin processing sequence, it has been shown that the receptor fragment that corresponds to a part of the extracellular domain is released and inhibits reelin signaling in primary neurons (Koch et al., 2002). In this case, and in others cases in which the ectodomain is released into the extracellular environment, the fragments can act in a dominant-negative fashion in the regulation of reelin signaling and in the diverse roles this ligand plays during embryonic brain development and in the adult brain. In the case of the ApoER2-CTF, this fragment could potentially serve as a scaffold platform for signaling processes taking place, for example, in the endosomal compartment that could be completed following γ -secretase processing. In addition, ApoER2-CTF could regulate the role of ApoER2-ICD and/or compete for the binding of adaptor proteins to the cytoplasmic tails of other receptors, such as LRP1 and APP. The binding of ApoER2-ICD to the cytoplasmic tails of these proteins has not been detected; however, as discussed previously and considering its association with different cytoplasmic proteins, it has the potential to modulate the function of these proteins (Fig. 3). For example, FE65 binding to AICD has been associated with the regulation of expression of cytoskeletal proteins, the regulation of neuronal cytoskeletal dynamics (Müller et al., 2006) and the expression of GSK3 and neuronal apoptosis (Kim et al., 2003). Therefore, if ApoER2-ICD competes with AICD, it could potentially regulate these and other roles of Fe65.

Proteolytic processing of other receptors of the family

In this review, the discussion has centered on LRP1, megalin/LRP2 and ApoER2 members of the LDLR receptor family. However, it is important to mention that other receptors also experience shedding and RIP and these events could be of functional relevance.

The tumor suppressor LRP1B

LRP1B or LRP1-DIT (Deleted in Tumor) is a receptor that has a high level of homology with LRP1 (Fig. 1), including its ectodomain processing by furin (Liu et al., 2001), is inactivated in several tumors (Nakagawa et al., 2006; Liu et al., 2000; Lu et al., 2010). LRP1B exhibits some interesting features that distinguish it from LRP1, including its slow rate of endocytosis (Liu et al., 2001; Knisely et al., 2007), which usually localizes LRP1B at the cell surface, and its restricted tissue expression (Li et al., 2005; Haas et al., 2011). LRP1B

binds to a common repertoire of ligands of LRP1 (Liu et al., 2001; Li et al., 2002; Cam et al., 2004; Haas et al., 2011), indicating that they could possibly have opposite roles. In accordance with this theory, LRP1B inhibits A β formation (Cam et al., 2004), uPAR regeneration and cell migration (Li et al., 2002), and LRP1B attenuates smooth muscle cell migration (Seki et al., 2005). Regarding the tumor suppressor function of the receptor, the ectodomain shedding of LRP1B and production of an LRP1B-ICD was shown to control negatively the anchorage-independent growth of the human neuroglioma cell line, H4 (Liu et al., 2006). As mentioned for other members of the receptor family, part of the function of the LRP1B ICD-containing fragment could be mediated by protein partners that recognize it (Table 1), and by the phosphorylation of the tail by PKC α (Shiroshima et al., 2009). It will be interesting to determine how much of the tumor suppressor function of the receptor depends upon the shedding and RIP of LRP1B, especially considering that the role of the sLRP1B during mouse development is critical and sLRP1B can replace the loss of the complete receptor (Dietrich et al., 2010; Marschang et al., 2004).

LRP5/6 and the Wnt/ β -catenin signaling pathway

A subclass of receptors within the LDLR family is composed of LRP5 and LRP6. These receptors are involved in the signaling pathway triggered by Wnt ligands, which is also referred to as the Wnt/canonical or the Wnt/ β -catenin pathway. The role of this pathway has relevance during development because it participates in gastrulation (Christian et al., 1991; Parr and McMahon, 1994), neural crest development (Tamai et al., 2000), neuronal differentiation (Toledo et al., 2008; Wodarz and Nusse, 1998; Cajánek et al., 2009) and organogenesis (Vainio et al., 1999; Gessert and Kühl, 2010; Niu et al., 2010). In addition, the Wnt/ β -catenin signaling pathway participates in stem cell maintenance (Zeng and Nusse, 2010), neurogenesis (Kalani et al., 2008) and neuronal survival and function (Cerpa et al., 2009). Alterations in this pathway have consequences in several pathologies, including certain types of cancer, such as colorectal tumors (Behrens and Lustig, 2004), osteoporosis (Agholme and Aspenberg, 2011) and AD (De Ferrari and Inestrosa, 2000; Inestrosa et al., 2002; Fuentealba et al., 2004; Inestrosa et al., 2007). The Wnt/ β -catenin pathway is activated when Wnt ligands bind to the seven-transmembrane receptor Frizzled (Fzl) and to the coreceptors LRP5 or LRP6 (Pinson et al., 2000; Tamai et al., 2000; Wehrli et al., 2000). In the absence of Wnt, the cytosolic levels of β -catenin are notably low. This low level of β -catenin is a result of its interaction with the so-called “destruction complex,” which is composed of the tumor suppressor APC, the scaffold proteins Axin and dishevelled (Dvl) and the kinases casein kinase I C γ (CKI γ) and GSK3 β . In this complex, β -catenin is sequentially phosphorylated by CKI γ and GSK3 β , it is ubiquitinated and is finally degraded in the proteasome (Aberle et al., 1997;

Orford et al., 1997). In the presence of the ligand that triggers the dimerization of Fzl and LRP5/6, the PPPSPxS cytosolic motifs of LRP5/6 are phosphorylated by CKI γ and GSK3 β (Davidson et al., 2005; Zeng et al., 2005; Zeng et al., 2007), promoting axin recruitment to the membrane. This process results in an increase in levels of β -catenin that translocates to the nucleus and binds the transcription proteins TCF/LEF and activates several Wnt target genes (Brannon et al., 1997; McKendry et al., 1997; Willert and Nusse, 1998). In addition to the recruitment of axin, the phosphorylation of LRP5/6 has several other consequences, including the inactivation of GSK3 β , the induction of Wnt signaling (Piao et al., 2008; Wu et al., 2009) and the aggregation of LRP6 to form a signalosome complex (Bilic et al., 2007). The observation that the phosphorylated cytosolic tail of LRP6 inactivates GSK3 β has stimulated interest among researchers in evaluating the inhibitory role of synthetic LRP6 ICDs on the activity of GSK3 β and the activation of the Wnt pathway (Mi and Johnson, 2005; Mi et al., 2005). These studies indicate that ICDs containing one (Davidson et al., 2005; Piao et al., 2008; Wu et al., 2009) or all of the PPPSPxS motifs (Mi and Johnson, 2005; Mi et al., 2005; Cselenyi et al., 2008), even in the absence of phosphorylation (Beagle et al., 2009), activates the signaling pathway (Davidson et al., 2005; Mi and Johnson, 2005; Mi et al., 2005; Cselenyi et al., 2008; Piao et al., 2008; Beagle et al., 2009; Wu et al., 2009). To make these observations physiologically relevant, it is important to determine if the receptor suffers RIP. Mi et al. showed that LRP6 is activated by Wnt3a and by PMA and releases a soluble form of the receptor (sLRP6). Interestingly, when a chimeric protein lacking the ectodomain but containing the transmembrane domain and tail of LRP6 is fused to Gal4/Vp16 and is expressed in CHO-k1 cells under the control of the Gal4-inducible HSV-TK promoter, the expression of luciferase is activated. This activation of expression and the detection of a 20 kDa fragment that could be the ICD are inhibited when γ -secretase activity is blocked. Related to the participation of the Wnt canonical pathway in cancer, it is interesting that the overexpression of a soluble form of LRP5, in an osteosarcoma cell line, inhibits the signaling pathway acting as a dominant negative form of the receptor (Guo et al., 2007). Moreover, the overexpression of sLRP5 was associated to a mesenchymal to epithelial transition and a reduction in the invasive and migratory phenotype of the cells (Guo et al., 2007).

In addition to the canonical Wnt signaling pathway, other Wnt ligands activate the Wnt-non-canonical pathway, which acts independently of LRP5/6, including the planar cell polarity (PCP) pathway and a pathway involving Ca²⁺ signaling (Slusarski et al., 1997; Boutros et al., 1998; Miller et al., 1999; Kühl et al., 2000). These alternative pathways are triggered by the binding of Wnt to Fzl and other coreceptors, such as the Ror-family receptor tyrosine kinases (RTKs) (Minami et al., 2010) and Derailed/Ryk (Yoshikawa et al., 2003; Lu et al., 2004). However, there is evidence indicating

that LRP6 binds and sequesters the non-canonical ligands Wnt5a and Wnt11 and functions as a negative regulator of the non-canonical signaling pathway (Bryja et al., 2008). Taking this under consideration, sLRP6 could function as a dominant-negative receptor, controlling one or several roles of the non-canonical pathways that include neural tube closure, orientation of cilia and sensory hair cells, axon guidance (Keller, 2002; Myers et al., 2002; Montcouquiol et al., 2003; Guo et al., 2004; Lu et al., 2004), cell motility and cancer (Saitoh et al., 2002; Weeraratna et al., 2002).

VLDLR, the other reelin receptor

The very low-density lipoprotein receptor (VLDLR), which is structurally similar to the LDL receptor, was discovered as a candidate for cholesterol homeostasis (Oka et al., 1994; Takahashi et al., 1992) (Fig. 1). Like ApoER2, VLDLR is expressed preferentially in the developing and adult brain, but VLDLR is also expressed in skeletal muscle, heart and adipocytes (Oka et al., 1994; Christie et al., 1996; Sakai et al., 2009). Similarly to ApoER2, VLDLR participates in brain development through signaling that is mediated by its ligand reelin and the adaptor Dab1 (Hiesberger et al., 1999; Trommsdorff et al., 1999) (as discussed earlier in section "ApoER2, a signaling receptor with an essential role in the CNS"). The involvement of VLDLR in brain development was demonstrated using VLDLR null mice, which have normal levels of plasma lipoproteins (Frykman et al., 1995) but exhibit defects in cerebellar development and in the anchorage of migrating neurons (Hack et al., 2007), and these defects are increased in VLDLR^{-/-} and ApoER2^{-/-} double-knockout animals (Trommsdorff et al., 1999). In the adult hippocampus, the expression of VLDLR is related to synaptic plasticity and LTP processes (Weeber et al., 2002). In addition to reelin (Yasui et al., 2010), VLDLR ligands include different isoforms of ApoE (E2, E3 and E4) (Ruiz et al., 2005), thrombospondin-1 (Blake et al., 2008) and F-spondin (Andrade et al., 2007).

Interestingly, VLDLR undergoes proteolytic processing in COS7 cells expressing the receptor, releasing a soluble fragment in the extracellular medium and a 20 kDa CTF, which accumulates after inhibiting γ -secretase complex, demonstrating that this protease is involved in the process (Hoe and Rebeck, 2005). The processing of the VLDLR ectodomain was inhibited by the ADAMs inhibitor TAPI-1, and processing increased following its interaction with ApoE (isoforms 2, 3 and 4), α 2M and reelin (Hoe and Rebeck, 2005). This processing is also regulated by structural features of the receptor itself. VLDLR is expressed as two different isoforms (Martensen et al., 1997; Iijima et al., 1998; Nakamura et al., 1998; Magrané et al., 1999). In the brain, VLDLR is found as a variant without an O-glycosylation domain (exon 16) and as an isoform lacking the O-glycosylation region and the third ligand binding repeat (exon 16 and exon 4) (Sakai et al., 2009). As discussed above

(ApoER2, section “ApoER2, a signaling receptor with an essential role in the CNS”), the isoform missing the O-glycosylation region does not associate with lipid rafts, and after reelin binding, it internalizes and a significant proportion of the receptor is recycled to the plasma membrane (Duit et al., 2010). It has been shown that a chimeric protein containing the O-glycosylated ectodomain of ApoER2 and the transmembrane-cytosolic region of VLDLR exhibits increased proteolytic processing compared to the VLDLR isoform lacking the O-glycosylation region. These findings demonstrate that this ectodomain of ApoER2 that allows the receptor to associate with lipid rafts is involved in proteolytic processing (Duit et al., 2010). However, whether or not there are differences in the processing of the natural VLDLR receptor isoforms that contain or do not contain the O-glycosylation region remains to be determined, and the functions of the proteolytic fragments that are derived from this receptor remain to be elucidated.

Concluding remarks

Classically, the receptors from the apolipoprotein E family were seen as endocytic proteins that played a role in the internalization of different ligands, especially lipoproteins, and LDL was the first physiologically relevant ligand to be described. Thereafter, signaling functions for many of these receptors have been described, despite the fact that they do not have intrinsic kinase activity. Regulating the expression and function of these receptors now includes proteolytic processing. Despite emerging evidence supporting the processing of these receptors, this field is in its infancy, and many new discoveries will develop, especially concerning the regulation of the proteolytic process and the functional consequences of the release of the products in several physiologic systems. It is possible that new animal models will help define the physiologic relevance of the proteolytic processing of the apolipoprotein E receptor family.

Acknowledgements

This work is supported by the Fondo Nacional de Ciencia y Tecnología, FONDECYT, grant # 1110382 and the Millennium Nucleus in Regenerative Biology (MINREB), P-07-011-F.

References

Abe J, Deguchi J, Matsumoto T, Takuwa N, Noda M, Ohno M, Makuuchi M, Kurokawa K, Takuwa Y (1997). Stimulated activation of platelet-derived growth factor receptor *in vivo* in balloon-injured arteries: a link between angiotensin II and intimal thickening. *Circulation*, 96(6): 1906–1913

Aberle H, Bauer A, Stappert J, Kispert A, Kemler R (1997). beta-catenin is a target for the ubiquitin-proteasome pathway. *EMBO J*, 16(13): 3797–3804

Agholme F, Aspenberg P (2011). Wnt signaling and orthopedics, an overview. *Acta Orthop*, 82(2): 125–130

Alvira-Botero X, Pérez-Gonzalez R, Spuch C, Vargas T, Antequera D, Garzón M, Bermejo-Pareja F, Carro E (2010). Megalin interacts with APP and the intracellular adapter protein FE65 in neurons. *Mol Cell Neurosci*, 45(3): 306–315

Ambjørn M, Asmussen J W, Lindstam M, Gottfryd K, Jacobsen C, Kiselyov V V, Moestrup S K, Penkowa M, Bock E, Berezin V (2008). Metallothionein and a peptide modeled after metallothionein, EmtinB, induce neuronal differentiation and survival through binding to receptors of the low-density lipoprotein receptor family. *J Neurochem*, 104(1): 21–37

An J, Zhang C, Polavarapu R, Zhang X, Zhang X, Yepes M (2008). Tissue-type plasminogen activator and the low-density lipoprotein receptor-related protein induce Akt phosphorylation in the ischemic brain. *Blood*, 112(7): 2787–2794

Andrade N, Komnenovic V, Blake S M, Jossin Y, Howell B, Goffinet A, Schneider W J, Nimpf J (2007). ApoER2/VLDL receptor and Dab1 in the rostral migratory stream function in postnatal neuronal migration independently of Reelin. *Proc Natl Acad Sci USA*, 104(20): 8508–8513

Andreasen P A, Sottrup-Jensen L, Kjøller L, Nykjaer A, Moestrup S K, Petersen C M, Gliemann J (1994). Receptor-mediated endocytosis of plasminogen activators and activator/inhibitor complexes. *FEBS Lett*, 338(3): 239–245

Arnaud L, Ballif B A, Förster E, Cooper J A (2003). Fyn tyrosine kinase is a critical regulator of disabled-1 during brain development. *Curr Biol*, 13(1): 9–17

Assadi A H, Zhang G, Beffert U, McNeil R S, Renfro A L, Niu S, Quattrocchi C C, Antalfy B A, Sheldon M, Armstrong D D, Wynshaw-Boris A, Herz J, D’Arcangelo G, Clark G D (2003). Interaction of reelin signaling and Lis1 in brain development. *Nat Genet*, 35(3): 270–276. Epub 2003 Oct 2026.

Assémat E, Châtelet F, Chandellier J, Commo F, Cases O, Verroust P, Kozyraki R (2005). Overlapping expression patterns of the multi-ligand endocytic receptors cubilin and megalin in the CNS, sensory organs and developing epithelia of the rodent embryo. *Gene Expr Patterns*, 6(1): 69–78

Bachinsky D R, Zheng G, Niles J L, McLaughlin M, Abbate M, Andres G, Brown D, McCluskey R T (1993). Detection of two forms of GP330. Their role in Heymann nephritis. *Am J Pathol*, 143(2): 598–611

Baker R N, Cancilla P A, Pollock P S, Frommes S P (1971). The movement of exogenous protein in experimental cerebral edema. An electron microscopic study after freeze-injury. *J Neuropathol Exp Neurol*, 30(4): 668–679

Ballif B A, Arnaud L, Arthur W T, Guris D, Imamoto A, Cooper J A (2004). Activation of a Dab1/CrkL/C3G/Rap1 pathway in Reelin-stimulated neurons. *Curr Biol*, 14(7): 606–610

Ballif B A, Arnaud L, Cooper J A (2003). Tyrosine phosphorylation of Disabled-1 is essential for Reelin-stimulated activation of Akt and Src family kinases. *Brain Res Mol Brain Res*, 117(2): 152–159

Bansal A, Gierasch L M (1991). The NPXY internalization signal of the LDL receptor adopts a reverse-turn conformation. *Cell*, 67(6): 1195–1201

Bar I, Goffinet A M (1999). Developmental neurobiology. Decoding the Reelin signal. *Nature*, 399(6737): 645–646

- Barker T H, Pallero M A, MacEwen M W, Tilden S G, Woods A, Murphy-Ullrich J E, Hagood J S (2004). Thrombospondin-1-induced focal adhesion disassembly in fibroblasts requires Thy-1 surface expression, lipid raft integrity, and Src activation. *J Biol Chem*, 279(22): 23510–23516
- Barnes H, Ackermann E J, van der Geer P (2003). v-Src induces Shc binding to tyrosine 63 in the cytoplasmic domain of the LDL receptor-related protein 1. *Oncogene*, 22(23): 3589–3597
- Barnes H, Larsen B, Tyers M, van Der Geer P (2001). Tyrosine-phosphorylated low density lipoprotein receptor-related protein 1 (Lrp1) associates with the adaptor protein SHC in SRC-transformed cells. *J Biol Chem*, 276(22): 19119–19125
- Barth J L, Argraves W S (2001). Cubilin and megalin: partners in lipoprotein and vitamin metabolism. *Trends Cardiovasc Med*, 11(1): 26–31
- Basu S, Binder R J, Ramalingam T, Srivastava P K (2001). CD91 is a common receptor for heat shock proteins gp96, hsp90, hsp70, and calreticulin. *Immunity*, 14(3): 303–313
- Beagle B, Mi K, Johnson G V (2009). Phosphorylation of PPP(S/T)P motif of the free LRP6 intracellular domain is not required to activate the Wnt/beta-catenin pathway and attenuate GSK3beta activity. *J Cell Biochem*, 108(4): 886–895
- Beffert U, Durudas A, Weeber E J, Stolt P C, Giehl K M, Sweatt J D, Hammer R E, Herz J (2006). Functional dissection of Reelin signaling by site-directed disruption of disabled-1 adaptor binding to apolipoprotein E receptor 2: distinct roles in development and synaptic plasticity. *J Neurosci*, 26(7): 2041–2052
- Beffert U, Morfini G, Bock H H, Reyna H, Brady S T, Herz J (2002). Reelin-mediated signaling locally regulates protein kinase B/Akt and glycogen synthase kinase 3beta. *J Biol Chem*, 277(51): 49958–49964
- Beffert U, Weeber E J, Durudas A, Qiu S, Masiulis I, Sweatt J D, Li W P, Adelman G, Frotscher M, Hammer R E, Herz J (2005). Modulation of synaptic plasticity and memory by Reelin involves differential splicing of the lipoprotein receptor Apoer2. *Neuron*, 47(4): 567–579
- Behrens J, Lustig B (2004). The Wnt connection to tumorigenesis. *Int J Dev Biol*, 48(5–6): 477–487
- Beisiegel U, Weber W, Ihrke G, Herz J, Stanley K K (1989). The LDL-receptor-related protein, LRP, is an apolipoprotein E-binding protein. *Nature*, 341(6238): 162–164
- Betts G N, van der Geer P, Komives E A (2008). Structural and functional consequences of tyrosine phosphorylation in the LRP1 cytoplasmic domain. *J Biol Chem*, 283(23): 15656–15664
- Biemesderfer D (2006). Regulated intramembrane proteolysis of megalin: linking urinary protein and gene regulation in proximal tubule? *Kidney Int*, 69(10): 1717–1721
- Bilic J, Huang Y L, Davidson G, Zimmermann T, Cruciat C M, Bienz M, Niehrs C (2007). Wnt induces LRP6 signalosomes and promotes dishevelled-dependent LRP6 phosphorylation. *Science*, 316(5831): 1619–1622
- Binder R J, Han D K, Srivastava P K (2000). CD91: a receptor for heat shock protein gp96. *Nat Immunol*, 1(2): 151–155
- Binder R J, Srivastava P K (2004). Essential role of CD91 in representation of gp96-chaperoned peptides. *Proc Natl Acad Sci USA*, 101(16): 6128–6133
- Birk H W, Piberhofer S, Schütterle G, Haase W, Kötting J, Koepsell H (1991). Analysis of Na⁺-D-glucose cotransporter and other renal brush border proteins in human urine. *Kidney Int*, 40(5): 823–837
- Blake S M, Strasser V, Andrade N, Duit S, Hofbauer R, Schneider W J, Nimpf J (2008). Thrombospondin-1 binds to ApoER2 and VLDL receptor and functions in postnatal neuronal migration. *EMBO J*, 27(22): 3069–3080
- Blaumueller C M, Qi H, Zagouras P, Artavanis-Tsakonas S (1997). Intracellular cleavage of Notch leads to a heterodimeric receptor on the plasma membrane. *Cell*, 90(2): 281–291
- Bock H H, Herz J (2003). Reelin activates SRC family tyrosine kinases in neurons. *Curr Biol*, 13(1): 18–26
- Bock H H, Jossin Y, Liu P, Forster E, May P, Goffinet A M, Herz J (2003). Phosphatidylinositol 3-kinase interacts with the adaptor protein Dab1 in response to Reelin signaling and is required for normal cortical lamination. *J Biol Chem*, 278(40): 38772–38779
- Boucher P, Gotthardt M, Li W P, Anderson R G, Herz J (2003). LRP: role in vascular wall integrity and protection from atherosclerosis. *Science*, 300(5617): 329–332
- Boucher P, Liu P, Gotthardt M, Hiesberger T, Anderson R G, Herz J (2002). Platelet-derived growth factor mediates tyrosine phosphorylation of the cytoplasmic domain of the low Density lipoprotein receptor-related protein in caveolae. *J Biol Chem*, 277(18): 15507–15513
- Boutros M, Paricio N, Strutt D I, Mlodzik M (1998). Dishevelled activates JNK and discriminates between JNK pathways in planar polarity and wingless signaling. *Cell*, 94(1): 109–118
- Bovenschen N, Mertens K, Hu L, Havekes L M, van Vlijmen B J (2005). LDL receptor cooperates with LDL receptor-related protein in regulating plasma levels of coagulation factor VIII *in vivo*. *Blood*, 106(3): 906–912
- Brannon M, Gomperts M, Sumoy L, Moon R T, Kimelman D (1997). A beta-catenin/XTcf-3 complex binds to the siamois promoter to regulate dorsal axis specification in *Xenopus*. *Genes Dev*, 11(18): 2359–2370
- Brown M S, Goldstein J L (1986). A receptor-mediated pathway for cholesterol homeostasis. *Science*, 232(4746): 34–47
- Bryja V, Andersson E R, Schambony A, Esner M, Bryjová L, Biris K K, Hall A C, Kraft B, Cajanek L, Yamaguchi T P, Buckingham M, Arenas E (2008). The extracellular domain of Lrp5/6 inhibits noncanonical Wnt signaling *in vivo*. *Mol Biol Cell*, 20(3): 924–936
- Bu G, Cam J, Zerbinatti C (2006). LRP in amyloid-beta production and metabolism. *Ann N Y Acad Sci*, 1086(1): 35–53
- Bu G, Maksymovitch E A, Schwartz A L (1993). Receptor-mediated endocytosis of tissue-type plasminogen activator by low density lipoprotein receptor-related protein on human hepatoma HepG2 cells. *J Biol Chem*, 268(17): 13002–13009
- Bu G, Marzolo M P (2000). Role of rap in the biogenesis of lipoprotein receptors. *Trends Cardiovasc Med*, 10(4): 148–155
- Bu G, Morton P A, Schwartz A L (1992a). Identification and partial characterization by chemical cross-linking of a binding protein for tissue-type plasminogen activator (t-PA) on rat hepatoma cells. A plasminogen activator inhibitor type 1-independent t-PA receptor. *J Biol Chem*, 267(22): 15595–15602
- Bu G, Schwartz A L (1998). RAP, a novel type of ER chaperone. *Trends Cell Biol*, 8(7): 272–276
- Bu G, Warshawsky I, Schwartz A L (1994). Cellular receptors for the plasminogen activators. *Blood*, 83(12): 3427–3436
- Bu G, Williams S, Strickland D K, Schwartz A L (1992b). Low density lipoprotein receptor-related protein/alpha 2-macroglobulin receptor is

- an hepatic receptor for tissue-type plasminogen activator. *Proc Natl Acad Sci USA*, 89(16): 7427–7431
- Burstyn-Cohen T, Frumkin A, Xu Y T, Scherer S S, Klar A (1998). Accumulation of F-spondin in injured peripheral nerve promotes the outgrowth of sensory axons. *J Neurosci*, 18(21): 8875–8885
- Buxbaum J D, Liu K N, Luo Y, Slack J L, Stocking K L, Peschon J J, Johnson R S, Castner B J, Cerretti D P, Black R A (1998). Evidence that tumor necrosis factor alpha converting enzyme is involved in regulated alpha-secretase cleavage of the Alzheimer amyloid protein precursor. *J Biol Chem*, 273(43): 27765–27767
- Cajánek L, Ribeiro D, Liste I, Parish C L, Bryja V, Arenas E (2009). Wnt/beta-catenin signaling blockade promotes neuronal induction and dopaminergic differentiation in embryonic stem cells. *Stem Cells*, 27(12): 2917–2927
- Cam J A, Zerinatti C V, Knisely J M, Hecimovic S, Li Y, Bu G (2004). The low density lipoprotein receptor-related protein 1B retains beta-amyloid precursor protein at the cell surface and reduces amyloid-beta peptide production. *J Biol Chem*, 279(28): 29639–29646
- Cao C, Lawrence D A, Li Y, Von Arnim C A, Herz J, Su E J, Makarova A, Hyman B T, Strickland D K, Zhang L (2006). Endocytic receptor LRP together with tPA and PAI-1 coordinates Mac-1-dependent macrophage migration. *EMBO J*, 25(9): 1860–1870
- Cao X, Südhof T C (2001). A transcriptionally [correction of transcriptively] active complex of APP with Fe65 and histone acetyltransferase Tip60. *Science*, 293(5527): 115–120
- Caporaso G L, Gandy S E, Buxbaum J D, Ramabhadran T V, Greengard P (1992). Protein phosphorylation regulates secretion of Alzheimer beta/A4 amyloid precursor protein. *Proc Natl Acad Sci USA*, 89(7): 3055–3059
- Carro E, Spuch C, Trejo J L, Antequera D, Torres-Aleman I (2005). Choroid plexus megalin is involved in neuroprotection by serum insulin-like growth factor I. *J Neurosci*, 25(47): 10884–10893
- Caruso-Neves C, Pinheiro A A, Cai H, Souza-Menezes J, Guggino W B (2006). PKB and megalin determine the survival or death of renal proximal tubule cells. *Proc Natl Acad Sci USA*, 103(49): 18810–18815
- Cerpa W, Toledo E M, Varela-Nallar L, Inestrosa N C (2009). The role of Wnt signaling in neuroprotection. *Drug News Perspect*, 22(10): 579–591
- Chai X, Förster E, Zhao S, Bock H H, Frotscher M (2009a). Reelin stabilizes the actin cytoskeleton of neuronal processes by inducing n-cofilin phosphorylation at serine3. *J Neurosci*, 29(1): 288–299
- Chai X, Förster E, Zhao S, Bock H H, Frotscher M (2009b). Reelin acts as a stop signal for radially migrating neurons by inducing phosphorylation of n-cofilin at the leading edge. *Commun Integr Biol*, 2(4): 375–377
- Chazaud B, Ricoux R, Christov C, Plonquet A, Gherardi R K, Barlovatz-Meimon G (2002). Promigratory effect of plasminogen activator inhibitor-1 on invasive breast cancer cell populations. *Am J Pathol*, 160(1): 237–246
- Chen C D, Podvin S, Gillespie E, Leeman S E, Abraham C R (2007). Insulin stimulates the cleavage and release of the extracellular domain of Klotho by ADAM10 and ADAM17. *Proc Natl Acad Sci USA*, 104(50): 19796–19801
- Cho S Y, Jeon J W, Lee S H, Park S S (2000). p67 isoform of mouse disabled 2 protein acts as a transcriptional activator during the differentiation of F9 cells. *Biochem J*, 352(3): 645–650
- Christ A, Terryn S, Schmidt V, Christensen E I, Huska M R, Andrade-Navarro M A, Hübner N, Devuyst O, Hammes A, Willnow T E (2010). The soluble intracellular domain of megalin does not affect renal proximal tubular function *in vivo*. *Kidney Int*, 78(5): 473–477
- Christensen E I, Birn H, Verroust P, Moestrup S K (1998). Megalin-mediated endocytosis in renal proximal tubule. *Ren Fail*, 20(2): 191–199
- Christensen E I, Moskaug J O, Vorum H, Jacobsen C, Gundersen T E, Nykjaer A, Blomhoff R, Willnow T E, Moestrup S K (1999). Evidence for an essential role of megalin in transepithelial transport of retinol. *J Am Soc Nephrol*, 10(4): 685–695
- Christian J L, Gavin B J, McMahon A P, Moon R T (1991). Isolation of cDNAs partially encoding four *Xenopus* Wnt-1/int-1-related proteins and characterization of their transient expression during embryonic development. *Dev Biol*, 143(2): 230–234
- Christie R H, Chung H, Rebeck G W, Strickland D, Hyman B T (1996). Expression of the very low-density lipoprotein receptor (VLDL-r), an apolipoprotein-E receptor, in the central nervous system and in Alzheimer's disease. *J Neuropathol Exp Neurol*, 55(4): 491–498
- Christoffersen C, Dahlbäck B, Nielsen L B (2006). Apolipoprotein M: progress in understanding its regulation and metabolic functions. *Scand J Clin Lab Invest*, 66(7): 631–638
- Chun J T, Wang L, Pasinetti G M, Finch C E, Zlokovic B V (1999). Glycoprotein 330/megalyn (LRP-2) has low prevalence as mRNA and protein in brain microvessels and choroid plexus. *Exp Neurol*, 157(1): 194–201
- Chung R S, Penkowa M, Dittmann J, King C E, Bartlett C, Asmussen J W, Hidalgo J, Carrasco J, Leung Y K, Walker A K, Fung S J, Dunlop S A, Fitzgerald M, Beazley L D, Chuah M I, Vickers J C, West A K (2008). Redefining the role of metallothionein within the injured brain: extracellular metallothioneins play an important role in the astrocyte-neuron response to injury. *J Biol Chem*, 283(22): 15349–15358
- Congote L F (2007). Serpin A1 and CD91 as host instruments against HIV-1 infection: are extracellular antiviral peptides acting as intracellular messengers? *Virus Res*, 125(2): 119–134
- Cselenyi C S, Jernigan K K, Tahinci E, Thorne C A, Lee L A, Lee E (2008). LRP6 transduces a canonical Wnt signal independently of Axin degradation by inhibiting GSK3's phosphorylation of beta-catenin. *Proc Natl Acad Sci USA*, 105(23): 8032–8037
- Cui S, Verroust P J, Moestrup S K, Christensen E I (1996). Megalin/gp330 mediates uptake of albumin in renal proximal tubule. *Am J Physiol*, 271(4 Pt 2): F900–F907
- Cuitino L, Matute R, Retamal C, Bu G, Inestrosa N C, Marzolo M P (2005). ApoER2 is endocytosed by a clathrin-mediated process involving the adaptor protein Dab2 independent of its Rafts' association. *Traffic*, 6(9): 820–838
- Culi J, Mann R S (2003). Boca, an endoplasmic reticulum protein required for wingless signaling and trafficking of LDL receptor family members in *Drosophila*. *Cell*, 112(3): 343–354
- Culi J, Springer T A, Mann R S (2004). Boca-dependent maturation of beta-propeller/EGF modules in low-density lipoprotein receptor proteins. *EMBO J*, 23(6): 1372–1380
- Czekay R P, Aertgeerts K, Curriden S A, Loskutoff D J (2003). Plasminogen activator inhibitor-1 detaches cells from extracellular matrices by inactivating integrins. *J Cell Biol*, 160(5): 781–791

- Czekay R P, Orlando R A, Woodward L, Lundstrom M, Farquhar M G (1997). Endocytic trafficking of megalin/RAP complexes: dissociation of the complexes in late endosomes. *Mol Biol Cell*, 8(3): 517–532
- D'Arcangelo G, Homayouni R, Keshvara L, Rice D S, Sheldon M, Curran T (1999). Reelin is a ligand for lipoprotein receptors. *Neuron*, 24(2): 471–479
- Davidson G, Wu W, Shen J, Bilic J, Fenger U, Stanek P, Glinka A, Niehrs C (2005). Casein kinase 1 gamma couples Wnt receptor activation to cytoplasmic signal transduction. *Nature*, 438(7069): 867–872
- De Ferrari G V, Inestrosa N C (2000). Wnt signaling function in Alzheimer's disease. *Brain Res Brain Res Rev*, 33(1): 1–12
- Didieu S, Langlois B, Devy J, Sid B, Henriot P, Sartelet H, Bellon G, Emonard H, Martiny L (2008). LRP-1 silencing prevents malignant cell invasion despite increased pericellular proteolytic activities. *Mol Cell Biol*, 28(9): 2980–2995
- Del Río J A, Heimrich B, Borrell V, Förster E, Drakew A, Alcántara S, Nakajima K, Miyata T, Ogawa M, Mikoshiba K, Derer P, Frotscher M, Soriano E (1997). A role for Cajal-Retzius cells and reelin in the development of hippocampal connections. *Nature*, 385(6611): 70–74
- Delarasse C, Auger R, Gonnord P, Fontaine B, Kanellopoulos J M (2011). The purinergic receptor P2X7 triggers alpha-secretase-dependent processing of the amyloid precursor protein. *J Biol Chem*, 286(4): 2596–2606
- Diaz-Rodríguez E, Montero J C, Esparís-Ogando A, Yuste L, Pandiella A (2002). Extracellular signal-regulated kinase phosphorylates tumor necrosis factor alpha-converting enzyme at threonine 735: a potential role in regulated shedding. *Mol Biol Cell*, 13(6): 2031–2044
- Dietrich M F, van der Weyden L, Prosser H M, Bradley A, Herz J, Adams D J (2010). Ectodomains of the LDL receptor-related proteins LRP1b and LRP4 have anchorage independent functions *in vivo*. *PLoS ONE*, 5(4): e9960
- Duit S, Mayer H, Blake S M, Schneider W J, Nimpf J (2010). Differential functions of ApoER2 and very low density lipoprotein receptor in Reelin signaling depend on differential sorting of the receptors. *J Biol Chem*, 285(7): 4896–4908
- Edwards D R, Handsley M M, Pennington C J (2008). The ADAM metalloproteinases. *Mol Aspects Med*, 29(5): 258–289
- Emonard H, Bellon G, de Diesbach P, Mettlen M, Hornebeck W, Courtoy P J (2005). Regulation of matrix metalloproteinase (MMP) activity by the low-density lipoprotein receptor-related protein (LRP). A new function for an “old friend”. *Biochimie*, 87(3–4): 369–376
- Emonard H, Bellon G, Troeberg L, Berton A, Robinet A, Henriot P, Marbaix E, Kirkegaard K, Patthy L, Eeckhout Y, Nagase H, Hornebeck W, Courtoy P J (2004). Low density lipoprotein receptor-related protein mediates endocytic clearance of pro-MMP-2-TIMP-2 complex through a thrombospondin-independent mechanism. *J Biol Chem*, 279(52): 54944–54951
- Endo K, Takino T, Miyamori H, Kinsen H, Yoshizaki T, Furukawa M, Sato H (2003). Cleavage of syndecan-1 by membrane type matrix metalloproteinase-1 stimulates cell migration. *J Biol Chem*, 278(42): 40764–40770
- Erdmann K S, Mao Y, McCrea H J, Zoncu R, Lee S, Paradise S, Modregger J, Biemesderfer D, Toomre D, De Camilli P (2007). A role of the Lowe syndrome protein OCRL in early steps of the endocytic pathway. *Dev Cell*, 13(3): 377–390
- Erranz B, Miquel J F, Argraves W S, Barth J L, Pimentel F, Marzolo M P (2004). Megalin and cubilin expression in gallbladder epithelium and regulation by bile acids. *J Lipid Res*, 45(12): 2185–2198
- Espirito Santo S M, Pires N M, Boesten L S, Gerritsen G, Bovenschen N, van Dijk K W, Jukema J W, Princen H M, Bensadoun A, Li W P, Herz J, Havekes L M, van Vlijmen B J (2004). Hepatic low-density lipoprotein receptor-related protein deficiency in mice increases atherosclerosis independent of plasma cholesterol. *Blood*, 103(10): 3777–3782
- Facciponte J G, MacDonald I J, Wang X Y, Kim H, Manjili M H, Subjeck J R (2005). Heat shock proteins and scavenger receptors: role in adaptive immune responses. *Immunol Invest*, 34(3): 325–342
- Fan H, Turck C W, Derynck R (2003). Characterization of growth factor-induced serine phosphorylation of tumor necrosis factor-alpha converting enzyme and of an alternatively translated polypeptide. *J Biol Chem*, 278(20): 18617–18627
- Fayard B, Bianchi F, Dey J, Moreno E, Djaffer S, Hynes N E, Monard D (2009). The serine protease inhibitor protease nexin-1 controls mammary cancer metastasis through LRP-1-mediated MMP-9 expression. *Cancer Res*, 69(14): 5690–5698
- Fears C Y, Gladson C L, Woods A (2006). Syndecan-2 is expressed in the microvasculature of gliomas and regulates angiogenic processes in microvascular endothelial cells. *J Biol Chem*, 281(21): 14533–14536
- Feinstein Y, Borrell V, Garcia C, Burstyn-Cohen T, Tzarfaty V, Frumkin A, Nose A, Okamoto H, Higashijima S, Soriano E, Klar A (1999). F-spondin and mindin: two structurally and functionally related genes expressed in the hippocampus that promote outgrowth of embryonic hippocampal neurons. *Development*, 126(16): 3637–3648
- Fisher C E, Howie S E (2006). The role of megalin (LRP-2/Gp330) during development. *Dev Biol*, 296(2): 279–297
- Fitzgerald M, Nairn P, Bartlett C A, Chung R S, West A K, Beazley L D (2007). Metallothionein-IIA promotes neurite growth via the megalin receptor. *Exp Brain Res*, 183(2): 171–180
- Fleming C E, Mar F M, Franquinho F, Saraiva M J, Sousa M M (2009). Transthyretin internalization by sensory neurons is megalin mediated and necessary for its neurotogenic activity. *J Neurosci*, 29(10): 3220–3232
- Fortini M E (2002). Gamma-secretase-mediated proteolysis in cell-surface-receptor signalling. *Nat Rev Mol Cell Biol*, 3(9): 673–684
- Fortini M E (2009). Notch signaling: the core pathway and its posttranslational regulation. *Dev Cell*, 16(5): 633–647
- Frykman P K, Brown M S, Yamamoto T, Goldstein J L, Herz J (1995). Normal plasma lipoproteins and fertility in gene-targeted mice homozygous for a disruption in the gene encoding very low density lipoprotein receptor. *Proc Natl Acad Sci USA*, 92(18): 8453–8457
- Fuentealba R A, Barria M I, Lee J, Cam J, Araya C, Escudero C A, Inestrosa N C, Bronfman F C, Bu G, Marzolo M P (2007). ApoER2 expression increases Abeta production while decreasing Amyloid Precursor Protein (APP) endocytosis: Possible role in the partitioning of APP into lipid rafts and in the regulation of gamma-secretase activity. *Mol Neurodegener*, 2(1): 14
- Fuentealba R A, Farias G, Scheu J, Bronfman M, Marzolo M P, Inestrosa N C (2004). Signal transduction during amyloid-beta-peptide neurotoxicity: role in Alzheimer disease. *Brain Res Brain Res Rev*, 47(1–3): 275–289

- Fuentealba R A, Liu Q, Kanekiyo T, Zhang J, Bu G (2009). Low density lipoprotein receptor-related protein 1 promotes anti-apoptotic signaling in neurons by activating Akt survival pathway. *J Biol Chem*, 284(49): 34045–34053
- Gajera C R, Emich H, Lioubinski O, Christ A, Beckervordersandforth-Bonk R, Yoshikawa K, Bachmann S, Christensen E I, Götz M, Kempermann G, Peterson A S, Willnow T E, Hammes A (2010). LRP2 in ependymal cells regulates BMP signaling in the adult neurogenic niche. *J Cell Sci*, 123(11): 1922–1930
- Gallagher H, Oleinikov A V, Fenske C, Newman D J (2004). The adaptor disabled-2 binds to the third psi xNPxY sequence on the cytoplasmic tail of megalin. *Biochimie*, 86(3): 179–182
- Garcia J H, Lossinsky A S, Kauffman F C, Conger K A (1978). Neuronal ischemic injury: light microscopy, ultrastructure and biochemistry. *Acta Neuropathol*, 43(1–2): 85–95
- García-Miranda P, Peral M J, Ilundain A A (2010). Rat small intestine expresses the reelin-Disabled-1 signalling pathway. *Exp Physiol*, 95(4): 498–507
- Gardai S J, McPhillips K A, Frasch S C, Janssen W J, Starefeldt A, Murphy-Ullrich J E, Bratton D L, Oldenburg P A, Michalak M, Henson P M (2005). Cell-surface calreticulin initiates clearance of viable or apoptotic cells through trans-activation of LRP on the phagocyte. *Cell*, 123(2): 321–334
- Garton K J, Gough P J, Blobel C P, Murphy G, Greaves D R, Dempsey P J, Raines E W (2001). Tumor necrosis factor- α -converting enzyme (ADAM17) mediates the cleavage and shedding of fractalkine (CX3CL1). *J Biol Chem*, 276(41): 37993–38001
- Gaultier A, Arandjelovic S, Li X, Janes J, Dragojlovic N, Zhou G P, Dolkas J, Myers R R, Gonias S L, Campana W M (2008). A shed form of LDL receptor-related protein-1 regulates peripheral nerve injury and neuropathic pain in rodents. *J Clin Invest*, 118(1): 161–172
- Gaultier A, Wu X, Le Moan N, Takimoto S, Mukandala G, Akassoglou K, Campana W M, Gonias S L (2009). Low-density lipoprotein receptor-related protein 1 is an essential receptor for myelin phagocytosis. *J Cell Sci*, 122(8): 1155–1162
- Gessert S, Kühl M (2010). The multiple phases and faces of wnt signaling during cardiac differentiation and development. *Circ Res*, 107(2): 186–199
- Gil C, Cubi R, Aguilera J (2007). Shedding of the p75NTR neurotrophin receptor is modulated by lipid rafts. *FEBS Lett*, 581(9): 1851–1858
- Goldstein J L, Brown M S, Anderson R G W, Russell D W, Schneider W J (1985). Receptor-mediated endocytosis: concepts emerging from the LDL receptor system. *Annu Rev Cell Biol*, 1(1): 1–39
- Gonzalez-Villalobos R, Klassen R B, Allen P L, Johanson K, Baker C B, Kobori H, Navar L G, Hammond T G (2005). Megalin binds and internalizes angiotensin-(1-7). *Am J Physiol Renal Physiol*, 290(5): F1270–F1275
- Gonzalez-Villalobos R, Klassen R B, Allen P L, Navar L G, Hammond T G (2005). Megalin binds and internalizes angiotensin II. *Am J Physiol Renal Physiol*, 288(2): F420–F427
- Gorovoy M, Gaultier A, Campana W M, Firestein G S, Gonias S L (2010). Inflammatory mediators promote production of shed LRP1/CD91, which regulates cell signaling and cytokine expression by macrophages. *J Leukoc Biol*, 88(4): 769–778
- Gotthardt M, Trommsdorff M, Nevitt M F, Shelton J, Richardson J A, Stockinger W, Nimpf J, Herz J (2000). Interactions of the low density lipoprotein receptor gene family with cytosolic adaptor and scaffold proteins suggest diverse biological functions in cellular communication and signal transduction. *J Biol Chem*, 275(33): 25616–25624
- Greenwood J A, Murphy-Ullrich J E (1998). Signaling of de-adhesion in cellular regulation and motility. *Microsc Res Tech*, 43(5): 420–432
- Guénette S, Chang Y, Hiesberger T, Richardson J A, Eckman C B, Eckman E A, Hammer R E, Herz J (2006). Essential roles for the FE65 amyloid precursor protein-interacting proteins in brain development. *EMBO J*, 25(2): 420–431
- Guénette S Y, Chang Y, Hyman B T, Tanzi R E, Rebeck G W (2002). Low-density lipoprotein receptor-related protein levels and endocytic function are reduced by overexpression of the FE65 adaptor protein, FE65L1. *J Neurochem*, 82(4): 755–762
- Guo N, Hawkins C, Nathans J (2004). Frizzled6 controls hair patterning in mice. *Proc Natl Acad Sci USA*, 101(25): 9277–9281
- Guo Y, Zi X, Koontz Z, Kim A, Xie J, Gorlick R, Holcombe R F, Hoang B H (2007). Blocking Wnt/LRP5 signaling by a soluble receptor modulates the epithelial to mesenchymal transition and suppresses met and metalloproteinases in osteosarcoma Saos-2 cells. *J Orthop Res*, 25(7): 964–971
- Guttman M, Betts G N, Barnes H, Ghassemian M, van der Geer P, Komives E A (2009). Interactions of the NPXY microdomains of the low density lipoprotein receptor-related protein 1. *Proteomics*, 9(22): 5016–5028
- Haas J, Beer A G, Widschwendter P, Oberdanner J, Salzmann K, Sarg B, Lindner H, Herz J, Patsch J R, Marschang P (2011). LRP1b shows restricted expression in human tissues and binds to several extracellular ligands, including fibrinogen and apoE-carrying lipoproteins. *Atherosclerosis*, 216(2): 342–347
- Hack I, Hellwig S, Junghans D, Brunne B, Bock H H, Zhao S, Frotscher M (2007). Divergent roles of ApoER2 and Vldlr in the migration of cortical neurons. *Development*, 134(21): 3883–3891
- Hahn-Dantona E, Ruiz J F, Bornstein P, Strickland D K (2001). The low density lipoprotein receptor-related protein modulates levels of matrix metalloproteinase 9 (MMP-9) by mediating its cellular catabolism. *J Biol Chem*, 276(18): 15498–15503
- Hama H, Saito A, Takeda T, Tanuma A, Xie Y, Sato K, Kazama J J, Gejyo F (2004). Evidence indicating that renal tubular metabolism of leptin is mediated by megalin but not by the leptin receptors. *Endocrinology*, 145(8): 3935–3940
- Hammad S M, Barth J L, Knaak C, Argraves W S (2000). Megalin acts in concert with cubilin to mediate endocytosis of high density lipoproteins. *J Biol Chem*, 275(16): 12003–12008
- Hammad S M, Ranganathan S, Loukinova E, Twal W O, Argraves W S (1997). Interaction of apolipoprotein J-amyloid beta-peptide complex with low density lipoprotein receptor-related protein-2/megalin. A mechanism to prevent pathological accumulation of amyloid beta-peptide. *J Biol Chem*, 272(30): 18644–18649
- Harris B, Pereira I, Parkin E (2009). Targeting ADAM10 to lipid rafts in neuroblastoma SH-SY5Y cells impairs amyloidogenic processing of the amyloid precursor protein. *Brain Res*, 1296: 203–215
- Hashimoto Y, Jiang H, Niikura T, Ito Y, Hagiwara A, Umezawa K, Abe Y, Murayama Y, Nishimoto I (2000). Neuronal apoptosis by apolipoprotein E4 through low-density lipoprotein receptor-related protein and heterotrimeric GTPases. *J Neurosci*, 20(22): 8401–8409
- Hay E, Faucheu C, Suc-Royer I, Touitou R, Stiot V, Vayssière B, Baron R, Roman-Roman S, Rawadi G (2005). Interaction between LRP5 and Frat1 mediates the activation of the Wnt canonical pathway. *J*

- Biol Chem, 280(14): 13616–13623
- Hayashida K, Bartlett A H, Chen Y, Park P W (2010). Molecular and cellular mechanisms of ectodomain shedding. *Anat Rec (Hoboken)*, 293(6): 925–937
- He X, Cooley K, Chung C H, Dashti N, Tang J (2007). Apolipoprotein receptor 2 and X11 alpha/beta mediate apolipoprotein E-induced endocytosis of amyloid-beta precursor protein and beta-secretase, leading to amyloid-beta production. *J Neurosci*, 27(15): 4052–4060
- Hermo L, Lustig M, Lefrancois S, Argraves W S, Morales C R (1999). Expression and regulation of LRP-2/megalin in epithelial cells lining the efferent ducts and epididymis during postnatal development. *Mol Reprod Dev*, 53(3): 282–293
- Herz J, Chen Y (2006). Reelin, lipoprotein receptors and synaptic plasticity. *Nat Rev Neurosci*, 7(11): 850–859
- Herz J, Clouthier D E, Hammer R E (1992a). LDL receptor-related protein internalizes and degrades uPA-PAI-1 complexes and is essential for embryo implantation. *Cell*, 71(3): 411–421
- Herz J, Clouthier D E, Hammer R E (1992b). LDL receptor-related protein internalizes and degrades uPA-PAI-1 complexes and is essential for embryo implantation. *Cell*, 71(3): 411–421
- Herz J, Willnow T E (1994). Functions of the LDL receptor gene family. *Ann N Y Acad Sci*, 737: 14–19
- Hiesberger T, Trommsdorff M, Howell B W, Goffinet A, Mumby M C, Cooper J A, Herz J (1999). Direct binding of Reelin to VLDL receptor and ApoE receptor 2 induces tyrosine phosphorylation of disabled-1 and modulates tau phosphorylation. *Neuron*, 24(2): 481–489
- Higashijima S, Nose A, Eguchi G, Hotta Y, Okamoto H (1997). Mindin/F-spondin family: novel ECM proteins expressed in the zebrafish embryonic axis. *Dev Biol*, 192(2): 211–227
- Higashiyama S, Nanba D (2005). ADAM-mediated ectodomain shedding of HB-EGF in receptor cross-talk. *Biochim Biophys Acta*, 1751(1): 110–117
- Hocevar B A, Mou F, Rennolds J L, Morris S M, Cooper J A, Howe P H (2003). Regulation of the Wnt signaling pathway by disabled-2 (Dab2). *EMBO J*, 22(12): 3084–3094
- Hocevar B A, Smine A, Xu X X, Howe P H (2001). The adaptor molecule Disabled-2 links the transforming growth factor beta receptors to the Smad pathway. *EMBO J*, 20(11): 2789–2801
- Hoe H S, Cooper M J, Burns M P, Lewis P A, van der Brug M, Chakraborty G, Cartagena C M, Pak D T, Cookson M R, Rebeck G W (2007). The metalloprotease inhibitor TIMP-3 regulates amyloid precursor protein and apolipoprotein E receptor proteolysis. *J Neurosci*, 27(40): 10895–10905
- Hoe H S, Magill L A, Guenette S, Fu Z, Vicini S, Rebeck G W (2006a). FE65 interaction with the ApoE receptor ApoEr2. *J Biol Chem*, 281(34): 24521–24530
- Hoe H S, Minami S S, Makarova A, Lee J, Hyman B T, Matsuoka Y, Rebeck G W (2008). Fyn modulation of Dab1 effects on amyloid precursor protein and ApoE receptor 2 processing. *J Biol Chem*, 283(10): 6288–6299
- Hoe H S, Pocivavsek A, Chakraborty G, Fu Z, Vicini S, Ehlers M D, Rebeck G W (2006b). Apolipoprotein E receptor 2 interactions with the N-methyl-D-aspartate receptor. *J Biol Chem*, 281(6): 3425–3431
- Hoe H S, Rebeck G W (2005). Regulation of ApoE receptor proteolysis by ligand binding. *Brain Res Mol Brain Res*, 137(1–2): 31–39
- Hoe H S, Tran T S, Matsuoka Y, Howell B W, Rebeck G W (2006c). DAB1 and Reelin effects on amyloid precursor protein and ApoE receptor 2 trafficking and processing. *J Biol Chem*, 281(46): 35176–35185
- Hoe H S, Wessner D, Beffert U, Becker A G, Matsuoka Y, Rebeck G W (2005). F-spondin interaction with the apolipoprotein E receptor ApoEr2 affects processing of amyloid precursor protein. *Mol Cell Biol*, 25(21): 9259–9268
- Hofmann S M, Zhou L, Perez-Tilve D, Greer T, Grant E, Wancata L, Thomas A, Pfluger P T, Basford J E, Gilham D, Herz J, Tschöp M H, Hui D Y (2007). Adipocyte LDL receptor-related protein-1 expression modulates postprandial lipid transport and glucose homeostasis in mice. *J Clin Invest*, 117(11): 3271–3282
- Holmbeck K, Bianco P, Caterina J, Yamada S, Kromer M, Kuznetsov S A, Mankani M, Robey P G, Poole A R, Pidoux I, Ward J M, Birkedal-Hansen H (1999). MT1-MMP-deficient mice develop dwarfism, osteopenia, arthritis, and connective tissue disease due to inadequate collagen turnover. *Cell*, 99(1): 81–92
- Homayouni R, Rice D S, Sheldon M, Curran T (1999). Disabled-1 binds to the cytoplasmic domain of amyloid precursor-like protein 1. *J Neurosci*, 19(17): 7507–7515
- Hsieh J C, Lee L, Zhang L, Wefer S, Brown K, DeRossi C, Wines M E, Rosenquist T, Holdener B C (2003). Mesd encodes an LRP5/6 chaperone essential for specification of mouse embryonic polarity. *Cell*, 112(3): 355–367
- Hu L, Boesten L S, May P, Herz J, Bovenschen N, Huisman M V, Berbée J F, Havekes L M, van Vlijmen B J, Tamsma J T (2006). Macrophage low-density lipoprotein receptor-related protein deficiency enhances atherosclerosis in ApoE/LDLR double knockout mice. *Arterioscler Thromb Vasc Biol*, 26(12): 2710–2715
- Huang S S, Ling T Y, Tseng W F, Huang Y H, Tang F M, Leal S M, Huang J S (2003). Cellular growth inhibition by IGFBP-3 and TGF-beta1 requires LRP-1. *FASEB J*, 17(14): 2068–2081
- Huovila A P, Turner A J, Pelto-Huikko M, Kärkkäinen I, Ortiz R M (2005). Shedding light on ADAM metalloproteinases. *Trends Biochem Sci*, 30(7): 413–422
- Iijima H, Miyazawa M, Sakai J, Magoori K, Ito M R, Suzuki H, Nose M, Kawarabayashi Y, Yamamoto T T (1998). Expression and characterization of a very low density lipoprotein receptor variant lacking the O-linked sugar region generated by alternative splicing. *J Biochem*, 124(4): 747–755
- Inestrosa N, De Ferrari G V, Garrido J L, Alvarez A, Olivares G H, Barría M I, Bronfman M, Chacón M A (2002). Wnt signaling involvement in beta-amyloid-dependent neurodegeneration. *Neurochem Int*, 41(5): 341–344
- Inestrosa N C, Varela-Nallar L, Grabowski C P, Colombres M (2007). Synaptotoxicity in Alzheimer's disease: the Wnt signaling pathway as a molecular target. *IUBMB Life*, 59(4): 316–321
- Izumiyama Y, Hirata M, Hasuwa H, Iwamoto R, Umata T, Miyado K, Tamai Y, Kurisaki T, Sehara-Fujisawa A, Ohno S, Mekada E (1998). A metalloprotease-disintegrin, MDC9/meltrin-gamma/ADAM9 and PKCdelta are involved in TPA-induced ectodomain shedding of membrane-anchored heparin-binding EGF-like growth factor. *EMBO J*, 17(24): 7260–7272
- Jacobsen K T, Adler L, Multhaupt G, Iverfeldt K (2010). Insulin-like growth factor-1 (IGF-1)-induced processing of amyloid-beta precursor protein (APP) and APP-like protein 2 is mediated by different metalloproteinases. *J Biol Chem*, 285(14): 10223–10231

- Jones C, Hammer R E, Li W P, Cohen J C, Hobbs H H, Herz J (2003). Normal sorting but defective endocytosis of the low density lipoprotein receptor in mice with autosomal recessive hypercholesterolemia. *J Biol Chem*, 278(31): 29024–29030
- Jorissen E, Prox J, Bernreuther C, Weber S, Schwanbeck R, Serneels L, Snellinx A, Craessaerts K, Thathiah A, Tesseur I, Bartsch U, Weskamp G, Blobel C P, Glatzel M, De Strooper B, Saftig P (2010). The disintegrin/metalloproteinase ADAM10 is essential for the establishment of the brain cortex. *J Neurosci*, 30(14): 4833–4844
- Jung F F, Bachinsky D R, Tang S S, Zheng G, Diamant D, Haveran L, McCluskey R T, Ingelfinger J R (1998). Immortalized rat proximal tubule cells produce membrane bound and soluble megalin. *Kidney Int*, 53(2): 358–366
- Jung H O, Uhm J S, Seo S M, Kim J H, Youn H J, Baek S H, Chung W S, Seung K B (2010). Angiotensin II-induced smooth muscle cell migration is mediated by LDL receptor-related protein 1 via regulation of matrix metalloproteinase 2 expression. *Biochem Biophys Res Commun*, 402(4): 577–582
- Kajita M, Itoh Y, Chiba T, Mori H, Okada A, Kinoh H, Seiki M (2001). Membrane-type 1 matrix metalloproteinase cleaves CD44 and promotes cell migration. *J Cell Biol*, 153(5): 893–904
- Kalani M Y, Cheshier S H, Cord B J, Bababegy S R, Vogel H, Weissman I L, Palmer T D, Nusse R (2008). Wnt-mediated self-renewal of neural stem/progenitor cells. *Proc Natl Acad Sci USA*, 105(44): 16970–16975
- Kanning K C, Hudson M, Amieux P S, Wiley J C, Bothwell M, Schecterson L C (2003). Proteolytic processing of the p75 neurotrophin receptor and two homologs generates C-terminal fragments with signaling capability. *J Neurosci*, 23(13): 5425–5436
- Karsdal M A, Larsen L, Engsig M T, Lou H, Ferreras M, Lochter A, Delaissé J M, Foged N T (2002). Matrix metalloproteinase-dependent activation of latent transforming growth factor-beta controls the conversion of osteoblasts into osteocytes by blocking osteoblast apoptosis. *J Biol Chem*, 277(46): 44061–44067
- Kasza A, Petersen H H, Heegaard C W, Oka K, Christensen A, Dubin A, Chan L, Andreasen P A (1997). Specificity of serine proteinase/serpin complex binding to very-low-density lipoprotein receptor and alpha2-macroglobulin receptor/low-density-lipoprotein-receptor-related protein. *Eur J Biochem*, 248(2): 270–281
- Keller R (2002). Shaping the vertebrate body plan by polarized embryonic cell movements. *Science*, 298(5600): 1950–1954
- Keshvara L, Benhayon D, Magdaleno S, Curran T (2001). Identification of reelin-induced sites of tyrosyl phosphorylation on disabled 1. *J Biol Chem*, 276(19): 16008–16014
- Killock D J, Ivetić A (2010). The cytoplasmic domains of TNFalpha-converting enzyme (TACE/ADAM17) and L-selectin are regulated differently by p38 MAPK and PKC to promote ectodomain shedding. *Biochem J*, 428(2): 293–304
- Kim D H, Iijima H, Goto K, Sakai J, Ishii H, Kim H J, Suzuki H, Kondo H, Saeki S, Yamamoto T (1996). Human apolipoprotein E receptor 2. A novel lipoprotein receptor of the low density lipoprotein receptor family predominantly expressed in brain. *J Biol Chem*, 271(14): 8373–8380
- Kim H S, Kim E M, Lee J P, Park C H, Kim S, Seo J H, Chang K A, Yu E, Jeong S J, Chong Y H, Suh Y H (2003). C-terminal fragments of amyloid precursor protein exert neurotoxicity by inducing glycogen synthase kinase-3beta expression. *FASEB J*, 17(13): 1951–1953
- Klassen R B, Crenshaw K, Kozyraki R, Verroust P J, Tio L, Atrian S, Allen P L, Hammond T G (2004). Megalin mediates renal uptake of heavy metal metallothionein complexes. *Am J Physiol Renal Physiol*, 287(3): F393–F403
- Knauer M F, Kridel S J, Hawley S B, Knauer D J (1997). The efficient catabolism of thrombin-protease nexin 1 complexes is a synergistic mechanism that requires both the LDL receptor-related protein and cell surface heparins. *J Biol Chem*, 272(46): 29039–29045
- Knauer M F, Orlando R A, Glabe C G (1996). Cell surface APP751 forms complexes with protease nexin 2 ligands and is internalized via the low density lipoprotein receptor-related protein (LRP). *Brain Res*, 740(1–2): 6–14
- Knisely J M, Li Y, Griffith J M, Geuze H J, Schwartz A L, Bu G (2007). Slow endocytosis of the LDL receptor-related protein 1B: implications for a novel cytoplasmic tail conformation. *Exp Cell Res*, 313(15): 3298–3307
- Koch S, Strasser V, Hauser C, Fasching D, Brandes C, Bajari T M, Schneider W J, Nimpf J (2002). A secreted soluble form of ApoE receptor 2 acts as a dominant-negative receptor and inhibits Reelin signaling. *EMBO J*, 21(22): 5996–6004
- Kojro E, Gimpl G, Lammich S, Marz W, Fahrenholz F (2001). Low cholesterol stimulates the nonamyloidogenic pathway by its effect on the alpha-secretase ADAM 10. *Proc Natl Acad Sci USA*, 98(10): 5815–5820
- König O, Rüttiger L, Müller M, Zimmermann U, Erdmann B, Kalbacher H, Gross M, Knipper M (2007). Estrogen and the inner ear: megalin knockout mice suffer progressive hearing loss. *FASEB J*, 22(2): 410–417
- Kounnas M Z, Church F C, Argraves W S, Strickland D K (1996). Cellular internalization and degradation of antithrombin III-thrombin, heparin cofactor II-thrombin, and alpha 1-antitrypsin-trypsin complexes is mediated by the low density lipoprotein receptor-related protein. *J Biol Chem*, 271(11): 6523–6529
- Kounnas M Z, Henkin J, Argraves W S, Strickland D K (1993). Low density lipoprotein receptor-related protein/alpha 2-macroglobulin receptor mediates cellular uptake of pro-urokinase. *J Biol Chem*, 268(29): 21862–21867
- Kounnas M Z, Moir R D, Rebeck G W, Bush A I, Argraves W S, Tanzi R E, Hyman B T, Strickland D K (1995). LDL receptor-related protein, a multifunctional ApoE receptor, binds secreted beta-amyloid precursor protein and mediates its degradation. *Cell*, 82(2): 331–340
- Kristensen T, Moestrup S K, Gliemann J, Bendtsen L, Sand O, Sottrup-Jensen L (1990). Evidence that the newly cloned low-density-lipoprotein receptor related protein (LRP) is the alpha 2-macroglobulin receptor. *FEBS Lett*, 276(1–2): 151–155
- Kühl M, Sheldahl L C, Park M, Miller J R, Moon R T (2000). The Wnt/Ca²⁺ pathway: a new vertebrate Wnt signaling pathway takes shape. *Trends Genet*, 16(7): 279–283
- Kuhn P H, Wang H, Dislich B, Colombo A, Zeitschel U, Ellwart J W, Kremmer E, Rossner S, Lichtenthaler S F (2010). ADAM10 is the physiologically relevant, constitutive alpha-secretase of the amyloid precursor protein in primary neurons. *EMBO J*, 29(17): 3020–3032
- Kuro-o M (2008). Endocrine FGFs and Klothos: emerging concepts. *Trends Endocrinol Metab*, 19(7): 239–245
- Kwon O Y, Hwang K, Kim J A, Kim K, Kwon I C, Song H K, Jeon H (2010). Dab1 binds to Fe65 and diminishes the effect of Fe65 or LRP1 on APP processing. *J Cell Biochem*, 111(2): 508–519

- Lanske B, Razzaque M S (2007). Vitamin D and aging: old concepts and new insights. *J Nutr Biochem*, 18(12): 771–777
- Larsson M, Hjälm G, Sakwe A M, Engström A, Höglund A S, Larsson E, Robinson R C, Sundberg C, Rask L (2003). Selective interaction of megalin with postsynaptic density-95 (PSD-95)-like membrane-associated guanylate kinase (MAGUK) proteins. *Biochem J*, 373(2): 381–391
- Lehste J R, Melsen F, Wellner M, Jansen P, Schlichting U, Renner-Müller I, Andreassen T T, Wolf E, Bachmann S, Nykjaer A, Willnow T E (2003). Hypocalcemia and osteopathy in mice with kidney-specific megalin gene defect. *FASEB J*, 17(2): 247–249
- Lehste J R, Rolinski B, Vorum H, Hilpert J, Nykjaer A, Jacobsen C, Aucouturier P, Moskaug J O, Otto A, Christensen E I, Willnow T E (1999). Megalin knockout mice as an animal model of low molecular weight proteinuria. *Am J Pathol*, 155(4): 1361–1370
- Lehti K, Rose N F, Valavaara S, Weiss S J, Keski-Oja J (2009). MT1-MMP promotes vascular smooth muscle dedifferentiation through LRP1 processing. *J Cell Sci*, 122(1): 126–135
- Lemjabbar-Alaoui H, Sidhu S S, Mengistab A, Gallup M, Basbaum C (2011). TACE/ADAM-17 phosphorylation by PKC-epsilon mediates premalignant changes in tobacco smoke-exposed lung cells. *PLoS ONE*, 6(3): e17489
- Lenting P J, Neels J G, van den Berg B M, Clijsters P P, Meijerman D W, Pannekoek H, van Mourik J A, Mertens K, van Zonneveld A J (1999). The light chain of factor VIII comprises a binding site for low density lipoprotein receptor-related protein. *J Biol Chem*, 274(34): 23734–23739
- Li Y, Bu G (2005). LRP5/6 in Wnt signaling and tumorigenesis. *Future Oncol*, 1(5): 673–681
- Li Y, Cong R, Biemesderfer D (2008). The COOH terminus of megalin regulates gene expression in opossum kidney proximal tubule cells. *Am J Physiol Cell Physiol*, 295(2): C529–C537
- Li Y, Knisely J M, Lu W, McCormick L M, Wang J, Henkin J, Schwartz A L, Bu G (2002). Low density lipoprotein (LDL) receptor-related protein 1B impairs urokinase receptor regeneration on the cell surface and inhibits cell migration. *J Biol Chem*, 277(44): 42366–42371
- Li Y, Lu W, Bu G (2005). Striking differences of LDL receptor-related protein 1B expression in mouse and human. *Biochem Biophys Res Commun*, 333(3): 868–873
- Li Y, Marzolo M P, van Kerkhof P, Strous G J, Bu G (2000). The YXXL motif, but not the two NPXY motifs, serves as the dominant endocytosis signal for low density lipoprotein receptor-related protein. *J Biol Chem*, 275(22): 17187–17194
- Li Y, Wood N, Donnelly P, Yellowlees D (1998a). Cell density and oestrogen both stimulate alpha 2-macroglobulin receptor expression in breast cancer cell T-47D. *Anticancer Res*, 18(2A): 1197–1202
- Li Y, Wood N, Grimsley P, Yellowlees D, Donnelly P K (1998b). *In vitro* invasiveness of human breast cancer cells is promoted by low density lipoprotein receptor-related protein. *Invasion Metastasis*, 18(5–6): 240–251
- Li Y, Wood N, Yellowlees D, Donnelly P (1997). Expression of alpha 2 macroglobulin receptor/low density lipoprotein receptor-related protein is cell culture density-dependent in human breast cancer cell line BT-20. *Biochem Biophys Res Commun*, 240(1): 122–127
- Lichtenthaler S F, Haass C, Steiner H (2011). Regulated intramembrane proteolysis—lessons from amyloid precursor protein processing. *J Neurochem*, 117(5): 779–796
- Lighthouse J K, Zhang L, Hsieh J C, Rosenquist T, Holdener B C (2010). MESD is essential for apical localization of megalin/LRP2 in the visceral endoderm. *Dev Dyn*: Lillis A P, Van Duyn L B, Murphy-Ullrich J E, Strickland D K (2008). LDL receptor-related protein 1: unique tissue-specific functions revealed by selective gene knockout studies. *Physiol Rev*, 88(3): 887–918
- Lillis K P, Enga A, White J A, Mertz J (2008). Two-photon imaging of spatially extended neuronal network dynamics with high temporal resolution. *Journal of Neuroscience Methods*, 172: 178–184
- Lin D C, Quevedo C, Brewer N E, Bell A, Testa J R, Grimes M L, Miller F D, Kaplan D R (2006). APPL1 associates with TrkA and GIPC1 and is required for nerve growth factor-mediated signal transduction. *Mol Cell Biol*, 26(23): 8928–8941
- Liu C X, Li Y, Obermoeller-McCormick L M, Schwartz A L, Bu G (2001). The putative tumor suppressor LRP1B, a novel member of the low density lipoprotein (LDL) receptor family, exhibits both overlapping and distinct properties with the LDL receptor-related protein. *J Biol Chem*, 276(31): 28889–28896
- Liu C X, Musco S, Lisitsina N M, Yaklichkin S Y, Lisitsyn N A (2000). Genomic organization of a new candidate tumor suppressor gene, LRP1B. *Genomics*, 69(2): 271–274
- Liu C X, Ranganathan S, Robinson S, Strickland D K (2006). gamma-Secretase-mediated release of the low density lipoprotein receptor-related protein 1B intracellular domain suppresses anchorage-independent growth of neuroglioma cells. *J Biol Chem*, 282(10): 7504–7511
- Liu Q, Zhang J, Tran H, Verbeek M M, Reiss K, Estus S, Bu G (2009). LRP1 shedding in human brain: roles of ADAM10 and ADAM17. *Mol Neurodegener*, 4(1): 17
- Logeat F, Bessia C, Brou C, LeBail O, Jarriault S, Seidah N G, Israël A (1998). The Notch1 receptor is cleaved constitutively by a furin-like convertase. *Proc Natl Acad Sci USA*, 95(14): 8108–8112
- Lou X, McQuistan T, Orlando R A, Farquhar M G (2002). GAIP, GIPC and Galphai3 are concentrated in endocytic compartments of proximal tubule cells: putative role in regulating megalin's function. *J Am Soc Nephrol*, 13(4): 918–927
- Loukinova E, Ranganathan S, Kuznetsov S, Gorlatova N, Migliorini M M, Loukinov D, Ulery P G, Mikhailenko I, Lawrence D A, Strickland D K (2002). Platelet-derived growth factor (PDGF)-induced tyrosine phosphorylation of the low density lipoprotein receptor-related protein (LRP). Evidence for integrated co-receptor function between LRP and the PDGF. *J Biol Chem*, 277(18): 15499–15506
- Lu W, Yamamoto V, Ortega B, Baltimore D (2004). Mammalian Ryk is a Wnt coreceptor required for stimulation of neurite outgrowth. *Cell*, 119(1): 97–108
- Lu Y J, Wu C S, Li H P, Liu H P, Lu C Y, Leu Y W, Wang C S, Chen L C, Lin K H, Chang Y S (2010). Aberrant methylation impairs low density lipoprotein receptor-related protein 1B tumor suppressor function in gastric cancer. *Genes Chromosomes Cancer*, 49(5): 412–424
- Lundgren S, Carling T, Hjälm G, Juhlin C, Rastad J, Pihlgren U, Rask L, Akerström G, Hellman P (1997). Tissue distribution of human gp330/megalyn, a putative Ca(2+)-sensing protein. *J Histochem Cytochem*, 45(3): 383–392
- MacDonald B T, Semenov M V, Huang H, He X (2011). Dissecting Molecular Differences between Wnt Coreceptors LRP5 and LRP6. *PLoS ONE*, 6(8): e23537

- Magrané J, Casaroli-Marano R P, Reina M, Gåfväls M, Vilaró S (1999). The role of O-linked sugars in determining the very low density lipoprotein receptor stability or release from the cell. *FEBS Lett*, 451 (1): 56–62
- Mantuano E, Inoue G, Li X, Takahashi K, Gaultier A, Gonias S L, Campana W M (2008). The hemopexin domain of matrix metalloproteinase-9 activates cell signaling and promotes migration of schwann cells by binding to low-density lipoprotein receptor-related protein. *J Neurosci*, 28(45): 11571–11582
- Mao J, Wang J, Liu B, Pan W, Farr G H 3rd, Flynn C, Yuan H, Takada S, Kimelman D, Li L, Wu D (2001). Low-density lipoprotein receptor-related protein-5 binds to Axin and regulates the canonical Wnt signaling pathway. *Mol Cell*, 7(4): 801–809
- Mao X, Kikani C K, Riojas R A, Langlais P, Wang L, Ramos F J, Fang Q, Christ-Roberts C Y, Hong J Y, Kim R Y, Liu F, Dong L Q (2006). APPL1 binds to adiponectin receptors and mediates adiponectin signalling and function. *Nat Cell Biol*, 8(5): 516–523
- Marcello E, Gardoni F, Mauceri D, Romorini S, Jeromin A, Epis R, Borroni B, Cattabeni F, Sala C, Padovani A, Di Luca M (2007). Synapse-associated protein-97 mediates alpha-secretase ADAM10 trafficking and promotes its activity. *J Neurosci*, 27(7): 1682–1691
- Marinò M, Zheng G, McCluskey R T (1999). Megalin (gp330) is an endocytic receptor for thyroglobulin on cultured fisher rat thyroid cells. *J Biol Chem*, 274(18): 12898–12904
- Marschang P, Brich J, Weeber E J, Sweatt J D, Shelton J M, Richardson J A, Hammer R E, Herz J (2004). Normal development and fertility of knockout mice lacking the tumor suppressor gene LRP1b suggest functional compensation by LRP1. *Mol Cell Biol*, 24(9): 3782–3793
- Martensen P M, Oka K, Christensen L, Rettenberger P M, Petersen H H, Christensen A, Chan L, Heegaard C W, Andreasen P A (1997). Breast carcinoma epithelial cells express a very low-density lipoprotein receptor variant lacking the O-linked glycosylation domain encoded by exon 16, but with full binding activity for serine proteinase/serpin complexes and Mr-40,000 receptor-associated protein. *Eur J Biochem*, 248(2): 583–591
- Martin A M, Kuhlmann C, Trossbach S, Jaeger S, Waldron E, Roebroek A, Luhmann H J, Laatsch A, Weggen S, Lessmann V, Pietrzik C U (2008). The functional role of the second NPXY motif of the LRP1 beta-chain in tissue-type plasminogen activator-mediated activation of N-methyl-D-aspartate receptors. *J Biol Chem*, 283(18): 12004–12013
- Marzolo M P, Bu G (2009). Lipoprotein receptors and cholesterol in APP trafficking and proteolytic processing, implications for Alzheimer's disease. *Semin Cell Dev Biol*, 20(2): 191–200
- Marzolo M P, Farfán P (2011). New insights into the roles of megalin/LRP2 and the regulation of its functional expression. *Biol Res*, 44(1): 89–105
- Marzolo M P, Yuseff M I, Retamal C, Donoso M, Ezquer F, Farfán P, Li Y, Bu G (2003). Differential distribution of low-density lipoprotein-receptor-related protein (LRP) and megalin in polarized epithelial cells is determined by their cytoplasmic domains. *Traffic*, 4(4): 273–288
- Massova I, Kotra L P, Fridman R, Mobashery S (1998). Matrix metalloproteinases: structures, evolution, and diversification. *FASEB J*, 12(12): 1075–1095
- Matsuno H, Yudoh K, Watanabe Y, Nakazawa F, Aono H, Kimura T (2001). Stromelysin-1 (MMP-3) in synovial fluid of patients with rheumatoid arthritis has potential to cleave membrane bound Fas ligand. *J Rheumatol*, 28(1): 22–28
- Matthews V, Schuster B, Schütze S, Bussmeyer I, Ludwig A, Hundhausen C, Sadowski T, Saftig P, Hartmann D, Kallen K J, Rose-John S (2003). Cellular cholesterol depletion triggers shedding of the human interleukin-6 receptor by ADAM10 and ADAM17 (TACE). *J Biol Chem*, 278(40): 38829–38839
- May P, Bock H H, Herz J (2003a). Integration of endocytosis and signal transduction by lipoprotein receptors. *Sci STKE*, 2003(176): 12pe
- May P, Bock H H, Nimpf J, Herz J (2003b). Differential glycosylation regulates processing of lipoprotein receptors by gamma-secretase. *J Biol Chem*, 278(39): 37386–37392
- May P, Reddy Y K, Herz J (2002). Proteolytic processing of low density lipoprotein receptor-related protein mediates regulated release of its intracellular domain. *J Biol Chem*, 277(21): 18736–18743
- May P, Rohlmann A, Bock H H, Zurhove K, Marth J D, Schomburg E D, Noebels J L, Beffert U, Sweatt J D, Weeber E J, Herz J (2004). Neuronal LRP1 functionally associates with postsynaptic proteins and is required for normal motor function in mice. *Mol Cell Biol*, 24(20): 8872–8883
- McCarthy R A, Barth J L, Chintalapudi M R, Knaak C, Argraves W S (2002). Megalin functions as an endocytic sonic hedgehog receptor. *J Biol Chem*, 277(28): 25660–25667
- McKendry R, Hsu S C, Harland R M, Grosschedl R (1997). LEF-1/TCF proteins mediate wnt-inducible transcription from the *Xenopus* nodal-related 3 promoter. *Dev Biol*, 192(2): 420–431
- McLoughlin D M, Miller C C (2008). The FE65 proteins and Alzheimer's disease. *J Neurosci Res*, 86(4): 744–754
- Merlos-Suárez A, Ruiz-Paz S, Baselga J, Arribas J (2001). Metalloprotease-dependent protransforming growth factor-alpha ectodomain shedding in the absence of tumor necrosis factor-alpha-converting enzyme. *J Biol Chem*, 276(51): 48510–48517
- Mi K, Dolan P J, Johnson G V (2005). The low density lipoprotein receptor-related protein 6 interacts with glycogen synthase kinase 3 and attenuates activity. *J Biol Chem*, 281(8): 4787–4794
- Mi K, Johnson G V (2005). Role of the intracellular domains of LRP5 and LRP6 in activating the Wnt canonical pathway. *J Cell Biochem*, 95(2): 328–338
- Mi K, Johnson G V (2007). Regulated proteolytic processing of LRP6 results in release of its intracellular domain. *J Neurochem*, 101(2): 517–529
- Miaczynska M, Christoforidis S, Giner A, Shevchenko A, Uttenweiler-Joseph S, Habermann B, Wilm M, Parton R G, Zerial M (2004). APPL proteins link Rab5 to nuclear signal transduction via an endosomal compartment. *Cell*, 116(3): 445–456
- Miller J R, Hocking A M, Brown J D, Moon R T (1999). Mechanism and function of signal transduction by the Wnt/beta-catenin and Wnt/Ca2+ pathways. *Oncogene*, 18(55): 7860–7872
- Miller S I, Ernst R K, Bader M W (2005). LPS, TLR4 and infectious disease diversity. *Nat Rev Microbiol*, 3(1): 36–46
- Minami Y, Oishi I, Endo M, Nishita M (2010). Ror-family receptor tyrosine kinases in noncanonical Wnt signaling: their implications in developmental morphogenesis and human diseases. *Dev Dyn*, 239(1): 1–15
- Mizuta K, Saito A, Watanabe T, Nagura M, Arakawa M, Shimizu F, Hoshino T (1999). Ultrastructural localization of megalin in the rat cochlear duct. *Hear Res*, 129(1–2): 83–91

- Moestrup S K, Gliemann J (1989). Purification of the rat hepatic alpha 2-macroglobulin receptor as an approximately 440-kDa single chain protein. *J Biol Chem*, 264(26): 15574–15577
- Moestrup S K, Kozyraki R, Kristiansen M, Kaysen J H, Rasmussen H H, Brault D, Pontillon F, Goda F O, Christensen E I, Hammond T G, Verroust P J (1998). The intrinsic factor-vitamin B12 receptor and target of teratogenic antibodies is a megalin-binding peripheral membrane protein with homology to developmental proteins. *J Biol Chem*, 273(9): 5235–5242
- Moestrup S K, Verroust P J (2001). Megalin- and cubilin-mediated endocytosis of protein-bound vitamins, lipids, and hormones in polarized epithelia. *Annu Rev Nutr*, 21(1): 407–428
- Montcouquiol M, Rachel R A, Lanford P J, Copeland N G, Jenkins N A, Kelley M W (2003). Identification of Vangl2 and Scrb1 as planar polarity genes in mammals. *Nature*, 423(6936): 173–177
- Morales C R, Igdoura S A, Wosu U A, Boman J, Argraves W S (1996). Low density lipoprotein receptor-related protein-2 expression in efferent duct and epididymal epithelia: evidence in rats for its *in vivo* role in endocytosis of apolipoprotein J/clusterin. *Biol Reprod*, 55(3): 676–683
- Morris S M, Arden S D, Roberts R C, Kendrick-Jones J, Cooper J A, Luzio J P, Buss F (2002a). Myosin VI binds to and localises with Dab2, potentially linking receptor-mediated endocytosis and the actin cytoskeleton. *Traffic*, 3(5): 331–341
- Morris S M, Cooper J A (2001). Disabled-2 colocalizes with the LDLR in clathrin-coated pits and interacts with AP-2. *Traffic*, 2(2): 111–123
- Morris S M, Tallquist M D, Rock C O, Cooper J A (2002b). Dual roles for the Dab2 adaptor protein in embryonic development and kidney transport. *EMBO J*, 21(7): 1555–1564
- Mu D, Cambier S, Fjellbirkeland L, Baron J L, Munger J S, Kawakatsu H, Sheppard D, Broadus V C, Nishimura S L (2002). The integrin alpha(v)beta8 mediates epithelial homeostasis through MT1-MMP-dependent activation of TGF-beta1. *J Cell Biol*, 157(3): 493–507
- Møller T, Concannon C G, Ward M W, Walsh C M, Tirniceriu A L, Tribl F, Kögel D, Prehn J H, Egensperger R (2006). Modulation of gene expression and cytoskeletal dynamics by the amyloid precursor protein intracellular domain (AICD). *Mol Biol Cell*, 18(1): 201–210
- Murphy G (2009). Regulation of the proteolytic disintegrin metalloproteinases, the ‘Sheddases’. *Semin Cell Dev Biol*, 20(2): 138–145
- Murphy-Ullrich J E, Höök M (1989). Thrombospondin modulates focal adhesions in endothelial cells. *J Cell Biol*, 109(3): 1309–1319
- Myers D C, Sepich D S, Solnica-Krezel L (2002). Convergence and extension in vertebrate gastrulae: cell movements according to or in search of identity? *Trends Genet*, 18(9): 447–455
- Naccache S N, Hasson T, Horowitz A (2006). Binding of internalized receptors to the PDZ domain of GIPC/synectin recruits myosin VI to endocytic vesicles. *Proc Natl Acad Sci USA*, 103(34): 12735–12740
- Nagai M, Meerloo T, Takeda T, Farquhar M G (2003). The adaptor protein ARH escorts megalin to and through endosomes. *Mol Biol Cell*, 14(12): 4984–4996
- Nakagawa T, Pimkhaokham A, Suzuki E, Omura K, Inazawa J, Imoto I (2006). Genetic or epigenetic silencing of low density lipoprotein receptor-related protein 1B expression in oral squamous cell carcinoma. *Cancer Sci*, 97(10): 1070–1074
- Nakamura Y, Yamamoto M, Kumamaru E (1998). A variant very low density lipoprotein receptor lacking 84 base pairs of O-linked sugar domain in the human brain myelin. *Brain Res*, 793(1–2): 47–53
- Neels J G, van Den Berg B M, Lookene A, Olivecrona G, Pannekoek H, van Zonneveld A J (1999). The second and fourth cluster of class A cysteine-rich repeats of the low density lipoprotein receptor-related protein share ligand-binding properties. *J Biol Chem*, 274(44): 31305–31311 (In Process Citation)
- Nielsen R, Birn H, Moestrup S K, Nielsen M, Verroust P, Christensen E I (1998). Characterization of a kidney proximal tubule cell line, LLC-PK1, expressing endocytotic active megalin. *J Am Soc Nephrol*, 9(10): 1767–1776
- Nielsen R, Courtoy P J, Jacobsen C, Dom G, Lima W R, Jadot M, Willnow T E, Devuyst O, Christensen E I (2007). Endocytosis provides a major alternative pathway for lysosomal biogenesis in kidney proximal tubular cells. *Proc Natl Acad Sci USA*, 104(13): 5407–5412
- Nishitsuji K, Hosono T, Nakamura T, Bu G, Michikawa M (2011). Apolipoprotein E regulates the integrity of tight junctions in an isoform-dependent manner in an *in vitro* blood-brain barrier model. *J Biol Chem*, 286(20): 17536–17542
- Niu X, Shi H, Peng J (2010). The role of mesodermal signals during liver organogenesis in zebrafish. *Sci China Life Sci*, 53(4): 455–461
- Norden A G, Lapsley M, Igarashi T, Kelleher C L, Lee P J, Matsuyama T, Scheinman S J, Shiraga H, Sundin D P, Thakker R V, Unwin R J, Verroust P, Moestrup S K (2002). Urinary megalin deficiency implicates abnormal tubular endocytic function in Fanconi syndrome. *J Am Soc Nephrol*, 13(1): 125–133
- Novak S, Hiesberger T, Schneider W J, Nimpf J (1996). A new low density lipoprotein receptor homologue with 8 ligand binding repeats in brain of chicken and mouse. *J Biol Chem*, 271(20): 11732–11736
- Nykjaer A, Dragun D, Walther D, Vorum H, Jacobsen C, Herz J, Melsen F, Christensen E I, Willnow T E (1999). An endocytic pathway essential for renal uptake and activation of the steroid 25-(OH) vitamin D3. *Cell*, 96(4): 507–515
- Nykjaer A, Petersen C M, Møller B, Jensen P H, Moestrup S K, Holtet T L, Etzerodt M, Thøgersen H C, Munch M, Andreasen P A (1992). Purified alpha 2-macroglobulin receptor/LDL receptor-related protein binds urokinase plasminogen activator inhibitor type-1 complex. Evidence that the alpha 2-macroglobulin receptor mediates cellular degradation of urokinase receptor-bound complexes. *J Biol Chem*, 267(21): 14543–14546
- Ogawa M (2000). Corticohistogenesis and Reelin signal cascade. *Nihon Shinkei Seishin Yakurigaku Zasshi*, 20(4): 169–174
- Ogawa M, Miyata T, Nakajima K, Yagy K, Seike M, Ikenaka K, Yamamoto H, Mikoshiba K (1995). The reeler gene-associated antigen on Cajal-Retzius neurons is a crucial molecule for laminar organization of cortical neurons. *Neuron*, 14(5): 899–912
- Ogden C A, deCathelineau A, Hoffmann P R, Bratton D, Ghebrehiwet B, Fadok V A, Henson P M (2001). C1q and mannose binding lectin engagement of cell surface calreticulin and CD91 initiates macropinocytosis and uptake of apoptotic cells. *J Exp Med*, 194(6): 781–796
- Ohuchi E, Imai K, Fujii Y, Sato H, Seiki M, Okada Y (1997). Membrane type 1 matrix metalloproteinase digests interstitial collagens and other extracellular matrix macromolecules. *J Biol Chem*, 272(4): 2446–2451
- Oka K, Ishimura-Oka K, Chu M J, Sullivan M, Krushkal J, Li W H, Chan L (1994). Mouse very-low-density-lipoprotein receptor (VLDLR) cDNA cloning, tissue-specific expression and evolutionary

- relationship with the low-density-lipoprotein receptor. *Eur J Biochem*, 224(3): 975–982
- Okada S S, Grobmyer S R, Barnathan E S (1996). Contrasting effects of plasminogen activators, urokinase receptor, and LDL receptor-related protein on smooth muscle cell migration and invasion. *Arterioscler Thromb Vasc Biol*, 16(10): 1269–1276
- Oleinikov A V, Zhao J, Makker S P (2000). Cytosolic adaptor protein Dab2 is an intracellular ligand of endocytic receptor gp600/megalin. *Biochem J*, 347(3): 613–621
- Orford K, Crockett C, Jensen J P, Weissman A M, Byers S W (1997). Serine phosphorylation-regulated ubiquitination and degradation of beta-catenin. *J Biol Chem*, 272(40): 24735–24738
- Orlando R A, Rader K, Authier F, Yamazaki H, Posner B I, Bergeron J J, Farquhar M G (1998). Megalin is an endocytic receptor for insulin. *J Am Soc Nephrol*, 9(10): 1759–1766
- Orr A W, Elzie C A, Kucik D F, Murphy-Ullrich J E (2003). Thrombospondin signaling through the calreticulin/LDL receptor-related protein co-complex stimulates random and directed cell migration. *J Cell Sci*, 116(14): 2917–2927
- Orr A W, Pallero M A, Murphy-Ullrich J E (2002). Thrombospondin stimulates focal adhesion disassembly through Gi- and phosphoinositide 3-kinase-dependent ERK activation. *J Biol Chem*, 277(23): 20453–20460
- Osono Y, Woollett L A, Herz J, Dietschy J M (1995). Role of the low density lipoprotein receptor in the flux of cholesterol through the plasma and across the tissues of the mouse. *J Clin Invest*, 95(3): 1124–1132
- Overton C D, Yancey P G, Major A S, Linton M F, Fazio S (2007). Deletion of macrophage LDL receptor-related protein increases atherogenesis in the mouse. *Circ Res*, 100(5): 670–677
- Parr B A, McMahon A P (1994). Wnt genes and vertebrate development. *Curr Opin Genet Dev*, 4(4): 523–528
- Patrie K M, Drescher A J, Goyal M, Wiggins R C, Margolis B (2001). The membrane-associated guanylate kinase protein MAGI-1 binds megalin and is present in glomerular podocytes. *J Am Soc Nephrol*, 12(4): 667–677
- Pedersen M O, Hansen P B, Nielsen S L, Penkowa M (2010). Metallothionein-I + II and receptor megalin are altered in relation to oxidative stress in cerebral lymphomas. *Leuk Lymphoma*, 51(2): 314–328
- Peiretti F, Deprez-Beauclair P, Bonardo B, Aubert H, Juhan-Vague I, Nalbone G (2003). Identification of SAP97 as an intracellular binding partner of TACE. *J Cell Sci*, 116(10): 1949–1957
- Petersen H H, Hilpert J, Militz D, Zandler V, Jacobsen C, Roebroek A J, Willnow T E (2003). Functional interaction of megalin with the megalinbinding protein (MegBP), a novel tetratricopeptide repeat-containing adaptor molecule. *J Cell Sci*, 116(3): 453–461
- Piao S, Lee S H, Kim H, Yum S, Stamos J L, Xu Y, Lee S J, Lee J, Oh S, Han J K, Park B J, Weis W I, Ha N C (2008). Direct inhibition of GSK3beta by the phosphorylated cytoplasmic domain of LRP6 in Wnt/beta-catenin signaling. *PLoS ONE*, 3(12): e4046
- Pietrzik C U, Busse T, Merriam D E, Weggen S, Koo E H (2002). The cytoplasmic domain of the LDL receptor-related protein regulates multiple steps in APP processing. *EMBO J*, 21(21): 5691–5700
- Pietrzik C U, Yoon I S, Jaeger S, Busse T, Weggen S, Koo E H (2004). FE65 constitutes the functional link between the low-density lipoprotein receptor-related protein and the amyloid precursor protein. *J Neurosci*, 24(17): 4259–4265
- Pilecka I, Banach-Orlowska M, Miaczynska M (2007). Nuclear functions of endocytic proteins. *Eur J Cell Biol*, 86(9): 533–547
- Pinson K I, Brennan J, Monkley S, Avery B J, Skarnes W C (2000). An LDL-receptor-related protein mediates Wnt signalling in mice. *Nature*, 407(6803): 535–538 (In Process Citation)
- Polavarapu R, An J, Zhang C, Yepes M (2008). Regulated intramembrane proteolysis of the low-density lipoprotein receptor-related protein mediates ischemic cell death. *Am J Pathol*, 172(5): 1355–1362
- Polavarapu R, Gongora M C, Yi H, Ranganathan S, Lawrence D A, Strickland D, Yepes M (2007). Tissue-type plasminogen activator-mediated shedding of astrocytic low-density lipoprotein receptor-related protein increases the permeability of the neurovascular unit. *Blood*, 109(8): 3270–3278
- Pompili V J, Gordon D, San H, Yang Z, Muller D W, Nabel G J, Nabel E G (1995). Expression and function of a recombinant PDGF B gene in porcine arteries. *Arterioscler Thromb Vasc Biol*, 15(12): 2254–2264
- Pujadas L, Gruart A, Bosch C, Delgado L, Teixeira C M, Rossi D, de Lecea L, Martínez A, Delgado-García J M, Soriano E (2010). Reelin regulates postnatal neurogenesis and enhances spine hypertrophy and long-term potentiation. *J Neurosci*, 30(13): 4636–4649
- Quinn K A, Grimsley P G, Dai Y P, Tapner M, Chesterman C N, Owensby D A (1997). Soluble low density lipoprotein receptor-related protein (LRP) circulates in human plasma. *J Biol Chem*, 272(38): 23946–23951
- Quinn K A, Pye V J, Dai Y P, Chesterman C N, Owensby D A (1999). Characterization of the soluble form of the low density lipoprotein receptor-related protein (LRP). *Exp Cell Res*, 251(2): 433–441
- Rader K, Orlando R A, Lou X, Farquhar M G (2000). Characterization of ANKRA, a novel ankyrin repeat protein that interacts with the cytoplasmic domain of megalin. *J Am Soc Nephrol*, 11(12): 2167–2178
- Reiss K, Ludwig A, Saftig P (2006). Breaking up the tie: disintegrin-like metalloproteinases as regulators of cell migration in inflammation and invasion. *Pharmacol Ther*, 111(3): 985–1006
- Rice D S, Sheldon M, D’Arcangelo G, Nakajima K, Goldowitz D, Curran T (1998). Disabled-1 acts downstream of Reelin in a signaling pathway that controls laminar organization in the mammalian brain. *Development*, 125(18): 3719–3729
- Riddell D R, Sun X M, Stannard A K, Soutar A K, Owen J S (2001). Localization of apolipoprotein E receptor 2 to caveolae in the plasma membrane. *J Lipid Res*, 42(6): 998–1002
- Riddell D R, Vinogradov D V, Stannard A K, Chadwick N, Owen J S (1999). Identification and characterization of LRP8 (apoER2) in human blood platelets. *J Lipid Res*, 40(10): 1925–1930
- Rohlmann A, Gotthardt M, Hammer R E, Herz J (1998). Inducible inactivation of hepatic LRP gene by cre-mediated recombination confirms role of LRP in clearance of chylomicron remnants. *J Clin Invest*, 101(3): 689–695
- Rowling M J, Kemmis C M, Taffany D A, Welsh J (2006). Megalin-mediated endocytosis of vitamin D binding protein correlates with 25-hydroxycholecalciferol actions in human mammary cells. *J Nutr*, 136(11): 2754–2759
- Rozañov D V, Hahn-Dantona E, Strickland D K, Strongin A Y (2003). The low density lipoprotein receptor-related protein LRP is regulated by membrane type-1 matrix metalloproteinase (MT1-MMP) proteo-

- lysis in malignant cells. *J Biol Chem*, 279(6): 4260–4268
- Rubera I, Poujeol C, Bertin G, Hasseine L, Counillon L, Poujeol P, Tauc M (2004). Specific Cre/Lox recombination in the mouse proximal tubule. *J Am Soc Nephrol*, 15(8): 2050–2056
- Ruiz J, Kouivaskaia D, Migliorini M, Robinson S, Saenko E L, Gorlatova N, Li D, Lawrence D, Hyman B T, Weisgraber K H, Strickland D K (2005). The apoE isoform binding properties of the VLDL receptor reveal marked differences from LRP and the LDL receptor. *J Lipid Res*, 46(8): 1721–1731
- Saenko E L, Yakhyayev A V, Mikhailenko I, Strickland D K, Sarafanov A G (1999). Role of the low density lipoprotein-related protein receptor in mediation of factor VIII catabolism. *J Biol Chem*, 274(53): 37685–37692
- Saito A, Pietromonaco S, Loo A K, Farquhar M G (1994). Complete cloning and sequencing of rat gp330/“megalin,” a distinctive member of the low density lipoprotein receptor gene family. *Proc Natl Acad Sci USA*, 91(21): 9725–9729
- Saitoh T, Mine T, Katoh M (2002). Frequent up-regulation of WNT5A mRNA in primary gastric cancer. *Int J Mol Med*, 9(5): 515–519
- Sakai K, Tiesel O, Ljungberg M C, Sullivan M, Lee H J, Terashima T, Li R, Kobayashi K, Lu H C, Chan L, Oka K (2009). A neuronal VLDLR variant lacking the third complement-type repeat exhibits high capacity binding of apoE containing lipoproteins. *Brain Res*, 1276: 11–21
- Salicioni A M, Gaultier A, Brownlee C, Cheezum M K, Gonias S L (2003). Low density lipoprotein receptor-related protein-1 promotes beta1 integrin maturation and transport to the cell surface. *J Biol Chem*, 279(11): 10005–10012
- Schlöndorff J, Lum L, Blobel C P (2001). Biochemical and pharmacological criteria define two shedding activities for TRANCE/OPGL that are distinct from the tumor necrosis factor alpha convertase. *J Biol Chem*, 276(18): 14665–14674
- Seiki M (2003). Membrane-type 1 matrix metalloproteinase: a key enzyme for tumor invasion. *Cancer Lett*, 194(1): 1–11
- Seki N, Bujo H, Jiang M, Tanaga K, Takahashi K, Yagui K, Hashimoto N, Schneider W J, Saito Y (2005). LRP1B is a negative modulator of increased migration activity of intimal smooth muscle cells from rabbit aortic plaques. *Biochem Biophys Res Commun*, 331(4): 964–970
- Selvais C, D’Auria L, Tyteca D, Perrot G, Lemoine P, Troeberg L, Dedieu S, Noël A, Nagase H, Henriot P, Courtoy P J, Marbaix E, Emonard H (2011). Cell cholesterol modulates metalloproteinase-dependent shedding of low-density lipoprotein receptor-related protein-1 (LRP-1) and clearance function. *FASEB J*, 25(8): 2770–2781
- Selvais C, Gaide Chevronnay H P, Lemoine P, Dedieu S, Henriot P, Courtoy P J, Marbaix E, Emonard H (2009). Metalloproteinase-dependent shedding of low-density lipoprotein receptor-related protein-1 ectodomain decreases endocytic clearance of endometrial matrix metalloproteinase-2 and -9 at menstruation. *Endocrinology*, 150(8): 3792–3799
- Sentürk A, Pfennig S, Weiss A, Burk K, Acker-Palmer A (2011). Ephrin Bs are essential components of the Reelin pathway to regulate neuronal migration. *Nature*, 472(7343): 356–360
- Shirakabe K, Wakatsuki S, Kurisaki T, Fujisawa-Sehara A (2001). Roles of Meltrin beta /ADAM19 in the processing of neuregulin. *J Biol Chem*, 276(12): 9352–9358
- Shiroshima T, Oka C, Kawaichi M (2009). Identification of LRP1B-interacting proteins and inhibition of protein kinase C-alpha-phosphorylation of LRP1B by association with PICK1. *FEBS Lett*, 583(1): 43–48
- Simó S, Pujadas L, Segura M F, La Torre A, Del Río J A, Ureña J M, Comella J X, Soriano E (2006). Reelin induces the detachment of postnatal subventricular zone cells and the expression of the Egr-1 through Erk1/2 activation. *Cereb Cortex*, 17(2): 294–303
- Skovronsky D M, Moore D B, Milla M E, Doms R W, Lee V M (2000). Protein kinase C-dependent alpha-secretase competes with beta-secretase for cleavage of amyloid-beta precursor protein in the trans-golgi network. *J Biol Chem*, 275(4): 2568–2575
- Slusarski D C, Corces V G, Moon R T (1997). Interaction of Wnt and a Frizzled homologue triggers G-protein-linked phosphatidylinositol signalling. *Nature*, 390(6658): 410–413
- Song H, Bu G (2009). MicroRNA-205 inhibits tumor cell migration through down-regulating the expression of the LDL receptor-related protein 1. *Biochem Biophys Res Commun*, 388(2): 400–405
- Song H, Li Y, Lee J, Schwartz A L, Bu G (2009). Low-density lipoprotein receptor-related protein 1 promotes cancer cell migration and invasion by inducing the expression of matrix metalloproteinases 2 and 9. *Cancer Res*, 69(3): 879–886
- Soond S M, Everson B, Riches D W, Murphy G (2005). ERK-mediated phosphorylation of Thr735 in TNFalpha-converting enzyme and its potential role in TACE protein trafficking. *J Cell Sci*, 118(11): 2371–2380
- Spoelgen R, Hammes A, Anzenberger U, Zechner D, Andersen O M, Jerchow B, Willnow T E (2005). LRP2/megalin is required for patterning of the ventral telencephalon. *Development*, 132(2): 405–414
- Stefansson S, Lawrence D A, Argraves W S (1996). Plasminogen activator inhibitor-1 and vitronectin promote the cellular clearance of thrombin by low density lipoprotein receptor-related proteins 1 and 2. *J Biol Chem*, 271(14): 8215–8220
- Stockinger W, Brandes C, Fasching D, Hermann M, Gotthardt M, Herz J, Schneider W J, Nimpf J (2000). The reelin receptor ApoER2 recruits JNK-interacting proteins-1 and-2. *J Biol Chem*, 275(33): 25625–25632
- Stockinger W, Hengstschläger-Ottner E, Novak S, Matus A, Hüttinger M, Bauer J, Lassmann H, Schneider W J, Nimpf J (1998). The low density lipoprotein receptor gene family. Differential expression of two alpha2-macroglobulin receptors in the brain. *J Biol Chem*, 273(48): 32213–32221
- Stockinger W, Sailler B, Strasser V, Recheis B, Fasching D, Kahr L, Schneider W J, Nimpf J (2002). The PX-domain protein SNX17 interacts with members of the LDL receptor family and modulates endocytosis of the LDL receptor. *EMBO J*, 21(16): 4259–4267
- Strickland D K, Ashcom J D, Williams S, Burgess W H, Migliorini M, Argraves W S (1990). Sequence identity between the alpha 2-macroglobulin receptor and low density lipoprotein receptor-related protein suggests that this molecule is a multifunctional receptor. *J Biol Chem*, 265(29): 17401–17404
- Strickland D K, Kounnas M Z, Argraves W S (1995). LDL receptor-related protein: a multiligand receptor for lipoprotein and proteinase catabolism. *FASEB J*, 9(10): 890–898
- Strickland D K, Ranganathan S (2003). Diverse role of LDL receptor-related protein in the clearance of proteases and in signaling. *J*

- Thromb Haemost, 1(7): 1663–1670
- Su H P, Nakada-Tsukui K, Tosello-Trampont A C, Li Y, Bu G, Henson P M, Ravichandran K S (2002). Interaction of CED-6/GULP, an adapter protein involved in engulfment of apoptotic cells with CED-1 and CD91/low density lipoprotein receptor-related protein (LRP). *J Biol Chem*, 277(14): 11772–11779
- Sundberg C, Thodeti C K, Kveiborg M, Larsson C, Parker P, Albrechtsen R, Wewer U M (2004). Regulation of ADAM12 cell-surface expression by protein kinase C epsilon. *J Biol Chem*, 279(49): 51601–51611
- Suzuki M, Raab G, Moses M A, Fernandez C A, Klagsbrun M (1997). Matrix metalloproteinase-3 releases active heparin-binding EGF-like growth factor by cleavage at a specific juxtamembrane site. *J Biol Chem*, 272(50): 31730–31737
- Suzuki Y, Nagai N, Yamakawa K, Kawakami J, Lijnen H R, Umemura K (2009). Tissue-type plasminogen activator (t-PA) induces stromelysin-1 (MMP-3) in endothelial cells through activation of lipoprotein receptor-related protein. *Blood*, 114(15): 3352–3358
- Takaguri A, Shirai H, Kimura K, Hinoki A, Eguchi K, Carlile-Klusacek M, Yang B, Rizzo V, Eguchi S (2011). Caveolin-1 negatively regulates a metalloprotease-dependent epidermal growth factor receptor transactivation by angiotensin II. *J Mol Cell Cardiol*, 50(3): 545–551
- Takahashi S, Kawarabayasi Y, Nakai T, Sakai J, Yamamoto T (1992). Rabbit very low density lipoprotein receptor: a low density lipoprotein receptor-like protein with distinct ligand specificity. *Proc Natl Acad Sci USA*, 89(19): 9252–9256
- Takayama Y, May P, Anderson R G, Herz J (2004). Low density lipoprotein receptor-related protein 1 (LRP1) controls endocytosis and c-CBL-mediated ubiquitination of the platelet-derived growth factor receptor beta (PDGFR beta). *J Biol Chem*, 280(18): 18504–18510
- Tamai K, Semenov M, Kato Y, Spokony R, Liu C, Katsuyama Y, Hess F, Saint-Jeannet J P, He X (2000). LDL-receptor-related proteins in Wnt signal transduction. *Nature*, 407(6803): 530–535 (In Process Citation)
- Tarr J, Eggleton P (2005). Immune function of C1q and its modulators CD91 and CD93. *Crit Rev Immunol*, 25(4): 305–330
- Tellier E, Canault M, Rebsomen L, Bonardo B, Juhan-Vague I, Nalbone G, Peiretti F (2006). The shedding activity of ADAM17 is sequestered in lipid rafts. *Exp Cell Res*, 312(20): 3969–3980
- Thiel K W, Carpenter G (2006). ErbB-4 and TNF-alpha converting enzyme localization to membrane microdomains. *Biochem Biophys Res Commun*, 350(3): 629–633
- Toledo E M, Colombres M, Inestrosa N C (2008). Wnt signaling in neuroprotection and stem cell differentiation. *Prog Neurobiol*, 86(3): 281–296
- Trommsdorff M, Borg J P, Margolis B, Herz J (1998). Interaction of cytosolic adaptor proteins with neuronal apolipoprotein E receptors and the amyloid precursor protein. *J Biol Chem*, 273(50): 33556–33560
- Trommsdorff M, Gotthardt M, Hiesberger T, Shelton J, Stockinger W, Nimpf J, Hammer R E, Richardson J A, Herz J (1999). Reeler/Disabled-like disruption of neuronal migration in knockout mice lacking the VLDL receptor and ApoE receptor 2. *Cell*, 97(6): 689–701
- Tsaroucha A K, Chatzaki E, Lambropoulou M, Despoudi K, Laftsidis P, Charsou C, Polychronidis A, Papadopoulos N, Simopoulos C E (2008). Megalin and cubilin in the human gallbladder epithelium. *Clin Exp Med*, 8(3): 165–170
- Tseng W F, Huang S S, Huang J S (2004). LRP-1/TbetaR-V mediates TGF-beta1-induced growth inhibition in CHO cells. *FEBS Lett*, 562(1–3): 71–78
- Ulery P G, Beers J, Mikhailenko I, Tanzi R E, Rebeck G W, Hyman B T, Strickland D K (2000). Modulation of beta-amyloid precursor protein processing by the low density lipoprotein receptor-related protein (LRP). Evidence that LRP contributes to the pathogenesis of Alzheimer's disease. *J Biol Chem*, 275(10): 7410–7415 (In Process Citation)
- Vainio S, Heikkilä M, Kispert A, Chin N, McMahon A P (1999). Female development in mammals is regulated by Wnt-4 signalling. *Nature*, 397(6718): 405–409
- van Kerkhof P, Lee J, McCormick L, Tetrault E, Lu W, Schoenfish M, Oorschot V, Strous G J, Klumperman J, Bu G (2005). Sorting nexin 17 facilitates LRP recycling in the early endosome. *EMBO J*, 24(16): 2851–2861
- Vandivier R W, Ogden C A, Fadok V A, Hoffmann P R, Brown K K, Botto M, Walport M J, Fisher J H, Henson P M, Greene K E (2002). Role of surfactant proteins A, D, and C1q in the clearance of apoptotic cells *in vivo* and *in vitro*: calreticulin and CD91 as a common collectin receptor complex. *J Immunol*, 169(7): 3978–3986
- Vassar R (2001). The beta-secretase, BACE: a prime drug target for Alzheimer's disease. *J Mol Neurosci*, 17(2): 157–170
- Vassar R, Bennett B D, Babu-Khan S, Kahn S, Mendiaz E A, Denis P, Teplow D B, Ross S, Amarante P, Loeloff R, Luo Y, Fisher S, Fuller J, Edenson S, Lile J, Jarosinski M A, Biere A L, Curran E, Burgess T, Louis J C, Collins F, Treanor J, Rogers G, Citron M (1999). Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. *Science*, 286(5440): 735–741
- von Arnim C A, Kinoshita A, Peltan I D, Tangredi M M, Herl L, Lee B M, Spoelgen R, Hshieh T T, Ranganathan S, Battey F D, Liu C X, Bacskaï B J, Sever S, Irizarry M C, Strickland D K, Hyman B T (2004). The low density lipoprotein receptor-related protein (LRP) is a novel beta-secretase (BACE1) substrate. *J Biol Chem*, 280(18): 17777–17785
- von Tresckow B, Kallen K J, von Strandmann E P, Borchmann P, Lange H, Engert A, Hansen H P (2004). Depletion of cellular cholesterol and lipid rafts increases shedding of CD30. *J Immunol*, 172(7): 4324–4331
- Wakabayashi T, De Strooper B (2008). Presenilins: members of the gamma-secretase quartets, but part-time soloists too. *Physiology (Bethesda)*, 23(4): 194–204
- Wakatsuki S, Kurisaki T, Sehara-Fujisawa A (2004). Lipid rafts identified as locations of ectodomain shedding mediated by Meltrin beta/ADAM19. *J Neurochem*, 89(1): 119–123
- Wang X, Lee S R, Arai K, Lee S R, Tsuji K, Rebeck G W, Lo E H (2003). Lipoprotein receptor-mediated induction of matrix metalloproteinase by tissue plasminogen activator. *Nat Med*, 9(10): 1313–1317
- Weaver A M, Hussaini I M, Mazar A, Henkin J, Gonias S L (1997). Embryonic fibroblasts that are genetically deficient in low density lipoprotein receptor-related protein demonstrate increased activity of the urokinase receptor system and accelerated migration on

- vitronectin. *J Biol Chem*, 272(22): 14372–14379
- Weeber E J, Beffert U, Jones C, Christian J M, Forster E, Sweatt J D, Herz J (2002). Reelin and ApoE receptors cooperate to enhance hippocampal synaptic plasticity and learning. *J Biol Chem*, 277(42): 39944–39952
- Weeraratna A T, Jiang Y, Hostetter G, Rosenblatt K, Duray P, Bittner M, Trent J M (2002). Wnt5a signaling directly affects cell motility and invasion of metastatic melanoma. *Cancer Cell*, 1(3): 279–288
- Wehrli M, Dougan S T, Caldwell K, O'Keefe L, Schwartz S, Vaizel-Ohayon D, Schejter E, Tomlinson A, DiNardo S (2000). arrow encodes an LDL-receptor-related protein essential for Wingless signalling. *Nature*, 407(6803): 527–530 (In Process Citation)
- Wicher G, Aldskogius H (2008). Megalin deficiency induces critical changes in mouse spinal cord development. *Neuroreport*, 19(5): 559–563
- Wicher G, Larsson M, Fex Svenningsen A, Gyllencreutz E, Rask L, Aldskogius H (2006). Low density lipoprotein receptor-related protein-2/megalin is expressed in oligodendrocytes in the mouse spinal cord white matter. *J Neurosci Res*, 83(5): 864–873
- Wicher G, Larsson M, Rask L, Aldskogius H (2005). Low-density lipoprotein receptor-related protein (LRP)-2/megalin is transiently expressed in a subpopulation of neural progenitors in the embryonic mouse spinal cord. *J Comp Neurol*, 492(2): 123–131
- Willert K, Nusse R (1998). Beta-catenin: a key mediator of Wnt signaling. *Curr Opin Genet Dev*, 8(1): 95–102
- Willnow T E (1999). The low-density lipoprotein receptor gene family: multiple roles in lipid metabolism. *J Mol Med (Berl)*, 77(3): 306–315 (see comments)
- Willnow T E, Hilpert J, Armstrong S A, Rohlmann A, Hammer R E, Burns D K, Herz J (1996a). Defective forebrain development in mice lacking gp330/megalin. *Proc Natl Acad Sci USA*, 93(16): 8460–8464
- Willnow T E, Moehring J M, Inocencio N M, Moehring T J, Herz J (1996b). The low-density-lipoprotein receptor-related protein (LRP) is processed by furin *in vivo* and *in vitro*. *Biochem J*, 313(Pt 1): 71–76
- Willnow T E, Nykjaer A, Herz J (1999). Lipoprotein receptors: new roles for ancient proteins. *Nat Cell Biol*, 1(6): E157–E162
- Willnow T E, Rohlmann A, Horton J, Otani H, Braun J R, Hammer R E, Herz J (1996c). RAP, a specialized chaperone, prevents ligand-induced ER retention and degradation of LDL receptor-related endocytic receptors. *EMBO J*, 15(11): 2632–2639
- Wodarz A, Nusse R (1998). Mechanisms of Wnt signaling in development. *Annu Rev Cell Dev Biol*, 14(1): 59–88
- Wolff N A, Abouhamed M, Verroust P J, Thévenod F (2006). Megalin-independent internalization of cadmium-metallothionein and cytotoxicity in cultured renal proximal tubule cells. *J Pharmacol Exp Ther*, 318(2): 782–791
- Wu G, Huang H, Garcia Abreu J, He X (2009). Inhibition of GSK3 phosphorylation of beta-catenin via phosphorylated PPPSPXS motifs of Wnt coreceptor LRP6. *PLoS ONE*, 4(3): e4926
- Wygrecka M, Wilhelm J, Jablonska E, Zakrzewicz D, Preissner K T, Seeger W, Guenther A, Markart P (2011). Shedding of Low Density Lipoprotein Receptor-related Protein-1 in Acute Respiratory Distress Syndrome. *Am J Respir Crit Care Med*: Xu X X, Yi T, Tang B, Lambeth J D (1998). Disabled-2 (Dab2) is an SH3 domain-binding partner of Grb2. *Oncogene*, 16(12): 1561–1569
- Xu X X, Yi T, Tang B, Lambeth J D (1998). Disabled-2 (Dab2) is an SH3 domain-binding partner of Grb2. *Oncogene*, 16(12): 1561–1569
- Yang D H, Cai K Q, Roland I H, Smith E R, Xu X X (2007). Disabled-2 is an epithelial surface positioning gene. *J Biol Chem*, 282(17): 13114–13122
- Yang M, Huang H, Li J, Li D, Wang H (2004). Tyrosine phosphorylation of the LDL receptor-related protein (LRP) and activation of the ERK pathway are required for connective tissue growth factor to potentiate myofibroblast differentiation. *FASEB J*, 18(15): 1920–1921
- Yang Z, Cool B H, Martin G M, Hu Q (2006). A dominant role for FE65 (APBB1) in nuclear signaling. *J Biol Chem*, 281(7): 4207–4214
- Yang Z, Strickland D K, Bornstein P (2001). Extracellular matrix metalloproteinase 2 levels are regulated by the low density lipoprotein-related scavenger receptor and thrombospondin 2. *J Biol Chem*, 276(11): 8403–8408
- Yasui N, Nogi T, Takagi J (2010). Structural basis for specific recognition of reelin by its receptors. *Structure*, 18(3): 320–331
- Yepes M, Sandkvist M, Moore E G, Bugge T H, Strickland D K, Lawrence D A (2003). Tissue-type plasminogen activator induces opening of the blood-brain barrier via the LDL receptor-related protein. *J Clin Invest*, 112(10): 1533–1540
- Yokozeki T, Wakatsuki S, Hatsuzawa K, Black R A, Wada I, Sehara-Fujisawa A (2007). Meltrin beta (ADAM19) mediates ectodomain shedding of Neuregulin beta1 in the Golgi apparatus: fluorescence correlation spectroscopic observation of the dynamics of ectodomain shedding in living cells. *Genes Cells*, 12(3): 329–343
- Yoshikawa S, McKinnon R D, Kokel M, Thomas J B (2003). Wnt-mediated axon guidance via the Drosophila Derailed receptor. *Nature*, 422(6932): 583–588
- Young H M, Anderson R B, Anderson C R (2004). Guidance cues involved in the development of the peripheral autonomic nervous system. *Auton Neurosci*, 112(1-2): 1–14
- Yuseff M I, Farfan P, Bu G, Marzolo M P (2007). A cytoplasmic PPPSP motif determines megalin's phosphorylation and regulates receptor's recycling and surface expression. *Traffic*, 8(9): 1215–1230
- Zambrano N, Minopoli G, de Candia P, Russo T (1998). The Fe65 adaptor protein interacts through its PID1 domain with the transcription factor CP2/LSF/LBP1. *J Biol Chem*, 273(32): 20128–20133
- Zeng X, Huang H, Tamai K, Zhang X, Harada Y, Yokota C, Almeida K, Wang J, Doble B, Woodgett J, Wynshaw-Boris A, Hsieh J C, He X (2007). Initiation of Wnt signaling: control of Wnt coreceptor Lrp6 phosphorylation/activation via frizzled, dishevelled and axin functions. *Development*, 135(2): 367–375
- Zeng X, Tamai K, Doble B, Li S, Huang H, Habas R, Okamura H, Woodgett J, He X (2005). A dual-kinase mechanism for Wnt coreceptor phosphorylation and activation. *Nature*, 438(7069): 873–877
- Zeng Y A, Nusse R (2010). Wnt proteins are self-renewal factors for mammary stem cells and promote their long-term expansion in culture. *Cell Stem Cell*, 6(6): 568–577
- Zerbinatti C V, Wozniak D F, Cirrito J, Cam J A, Osaka H, Bales K R, Zhuo M, Paul S M, Holtzman D M, Bu G (2004). Increased soluble amyloid-beta peptide and memory deficits in amyloid model mice overexpressing the low-density lipoprotein receptor-related protein. *Proc Natl Acad Sci USA*, 101(4): 1075–1080
- Zhang C, An J, Haile W B, Echeverry R, Strickland D K, Yepes M (2009). Microglial low-density lipoprotein receptor-related protein 1 mediates the effect of tissue-type plasminogen activator on matrix

- metalloproteinase-9 activity in the ischemic brain. *J Cereb Blood Flow Metab*, 29(12): 1946–1954
- Zhang Q, Thomas S M, Lui V W, Xi S, Siegfried J M, Fan H, Smithgall T E, Mills G B, Grandis J R (2006). Phosphorylation of TNF-alpha converting enzyme by gastrin-releasing peptide induces amphiregulin release and EGF receptor activation. *Proc Natl Acad Sci USA*, 103(18): 6901–6906
- Zheng G, Marino M, Zhao J, McCluskey R T (1998). Megalin (gp330): a putative endocytic receptor for thyroglobulin (Tg). *Endocrinology*, 139(3): 1462–1465
- Zheng Y, Schlondorff J, Blobel C P (2002). Evidence for regulation of the tumor necrosis factor alpha-convertase (TACE) by protein-tyrosine phosphatase PTPH1. *J Biol Chem*, 277(45): 42463–42470
- Zhou J, Hsieh J T (2001). The inhibitory role of DOC-2/DAB2 in growth factor receptor-mediated signal cascade. DOC-2/DAB2-mediated inhibition of ERK phosphorylation via binding to Grb2. *J Biol Chem*, 276(30): 27793–27798
- Zhu Y, Hui D Y (2003). Apolipoprotein E binding to low density lipoprotein receptor-related protein-1 inhibits cell migration via activation of cAMP-dependent protein kinase A. *J Biol Chem*, 278(38): 36257–36263
- Zhuo M, Holtzman D M, Li Y, Osaka H, DeMaro J, Jacquin M, Bu G (2000). Role of tissue plasminogen activator receptor LRP in hippocampal long-term potentiation. *J Neurosci*, 20(2): 542–549
- Zimina E P, Bruckner-Tuderman L, Franzke C W (2005). Shedding of collagen XVII ectodomain depends on plasma membrane microenvironment. *J Biol Chem*, 280(40): 34019–34024
- Zlokovic B V, Martel C L, Matsubara E, McComb J G, Zheng G, McCluskey R T, Frangione B, Ghiso J (1996). Glycoprotein 330/megalin: probable role in receptor-mediated transport of apolipoprotein J alone and in a complex with Alzheimer disease amyloid beta at the blood-brain and blood-cerebrospinal fluid barriers. *Proc Natl Acad Sci USA*, 93(9): 4229–4234
- Zou Z, Chung B, Nguyen T, Mentone S, Thomson B, Biemesderfer D (2004). Linking receptor-mediated endocytosis and cell signaling: evidence for regulated intramembrane proteolysis of megalin in proximal tubule. *J Biol Chem*, 279(33): 34302–34310
- Zurhove K, Nakajima C, Herz J, Bock H H, May P (2008). Gamma-secretase limits the inflammatory response through the processing of LRP1. *Sci Signal*, 1(47): ra15